###begin article-title 0
Aprataxin, causative gene product for EAOH/AOA1, repairs DNA single-strand breaks with damaged 3'-phosphate and 3'-phosphoglycolate ends
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 746 754 739 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 778 783 <span type="species:ncbi:9606">human</span>
Aprataxin is the causative gene product for early-onset ataxia with ocular motor apraxia and hypoalbuminemia/ataxia with oculomotor apraxia type 1 (EAOH/AOA1), the clinical symptoms of which are predominantly neurological. Although aprataxin has been suggested to be related to DNA single-strand break repair (SSBR), the physiological function of aprataxin remains to be elucidated. DNA single-strand breaks (SSBs) continually produced by endogenous reactive oxygen species or exogenous genotoxic agents, typically possess damaged 3'-ends including 3'-phosphate, 3'-phosphoglycolate, or 3'-alpha, beta-unsaturated aldehyde ends. These damaged 3'-ends should be restored to 3'-hydroxyl ends for subsequent repair processes. Here we demonstrate by in vitro assay that recombinant human aprataxin specifically removes 3'-phosphoglycolate and 3'-phosphate ends at DNA 3'-ends, but not 3'-alpha, beta-unsaturated aldehyde ends, and can act with DNA polymerase beta and DNA ligase III to repair SSBs with these damaged 3'-ends. Furthermore, disease-associated mutant forms of aprataxin lack this removal activity. The findings indicate that aprataxin has an important role in SSBR, that is, it removes blocking molecules from 3'-ends, and that the accumulation of unrepaired SSBs with damaged 3'-ends underlies the pathogenesis of EAOH/AOA1. The findings will provide new insight into the mechanism underlying degeneration and DNA repair in neurons.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 302 305 302 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3 B4 B5 B6">3&#8211;6</xref>
###xml 551 555 551 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7 B8 B9 B10">7&#8211;10</xref>
###xml 727 728 727 728 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 729 730 729 730 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 907 912 907 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12 B13 B14 B15">12&#8211;15</xref>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
Aprataxin is the causative gene product for early-onset ataxia with ocular motor apraxia and hypoalbuminemia, also called ataxia with oculomotor apraxia type 1 (EAOH/AOA1) (1,2), which is characterized by early-onset progressive ataxia, ocular motor apraxia, peripheral neuropathy and hypoalbuminemia (3-6). Aprataxin interacts with the X-ray repair cross-complementing group 1 protein (XRCC1) and poly(ADP-ribose) polymerase-1 (PARP-1), which are a scaffold protein and a molecular nick sensor in DNA single-strand break repair (SSBR), respectively (7-10), suggesting that aprataxin is associated with SSBR. Consistent with these observations, the lymphoblastoid cells from patients with EAOH/AOA1 show a high sensitivity to H2O2 and alkylating agents, which cause DNA single-strand breaks (SSBs) (11). In addition, aprataxin has the histidine triad (HIT) motif, which functions as nucleotidyl hydrolases (12-15), and the zinc finger motif, which is a DNA- or RNA-binding motif. These findings led to the hypothesis that aprataxin has catalytic activity in SSBR.
###end p 4
###begin p 5
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 815 817 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
SSBs are discontinuities in the sugar-phosphate backbone of one strand of a DNA duplex. In neurons, DNA is under continuous threat of damage by endogenous reactive oxygen species (ROS) or exogenous environmental genotoxins, and more than tens of thousands of SSBs arise in each cell per day (16). SSBs can arise directly from sugar damage, or indirectly from base damage via the enzymatic cleavage of the phosphodiester backbone as intermediate products of SSBR (16). The formation of another type of SSB is mediated by topoisomerase I (TOP1), which cleaves one strand of a DNA duplex during transcription or DNA replication (17,18). If SSBs are not repaired rapidly, they can cause transcription blockage or they are converted to lethal DNA double-strand breaks (DSBs), leading to cell dysfunction and cell death (19).
###end p 5
###begin p 6
###xml 270 271 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 883 885 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1025 1030 993 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21 B22 B23">21&#8211;23</xref>
Most SSBs are accompanied by the loss of a single nucleotide; this loss must be filled by DNA polymerase and subsequently sealed by DNA ligase. DNA polymerase beta (Pol beta) and DNA ligase III (Lig3) are most commonly employed for gap filling and ligation during SSBR (8). SSBs arising directly from sugar damage or indirectly from base damage typically possess damaged 3'-ends: 3'-phosphate, 3'-phosphoglycolate (3'-PG), or 3'-alpha, beta-unsaturated aldehyde ends. Because these damaged 3'-ends are not suitable for DNA polymerase or DNA ligase, enzymatic processing is required in SSBR to restore the damaged 3'-ends to suitable 3'-hydroxyl ends. 5'-Polynucleotide kinase 3'-phosphatase (PNKP) removes damaged 3'-phosphate ends, but not other damaged 3'-ends. Apurinic/apyrimidinic endonuclease (APE1) can remove 3'-phosphate, 3'-PG and 3'-alpha, beta-unsaturated aldehyde ends (20). However, the 3'-PG and 3'-phosphate removal activities of APE1 are approximately70-fold lower than the AP endonuclease activity of APE1 (21-23). Therefore, it is assumed that other enzymes can alternatively process these damaged 3'-ends.
###end p 6
###begin p 7
In the present study, we hypothesized that aprataxin removes damaged 3'-ends and facilitates the repair of SSBs. Here we show that aprataxin has a novel removal activity with a unique substrate specificity toward damaged 3'-ends including 3'-PG and 3'-phosphate ends, and that disease-associated mutant forms of aprataxin lack this activity. The results indicate that aprataxin has an important and direct role in SSBR, that is, it removes blocking molecules from DNA 3'-ends, and that neurodegeneration in EAOH/AOA1 may be caused by the accumulation of unrepaired SSBs with damaged 3'-ends.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Expression and purification of recombinant aprataxin
###end title 9
###begin p 10
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 233 238 <span type="species:ncbi:9606">Human</span>
###xml 1053 1058 <span type="species:ncbi:9606">human</span>
###xml 1682 1687 <span type="species:ncbi:42554">Tetra</span>
The long-form human aprataxin cDNA (GenBank accession number NM_175073) was amplified by polymerase chain reaction (PCR) using the primers 5'-CCGGATCCATGATGCGGGTGTGCTGGTTGG and 3'-GGCTCGAGTCACTGTGTCCAGTGCTTCCTG and the cDNA library (Human Ovary Marathon-Ready cDNA: Clonetech) as the template. The aprataxin cDNA fragment was inserted into the BamHI/XhoI site of the pFastBactrade mark donor plasmid, and this plasmid was transformed in DH10Bactrade mark competent cells to transpose into 'Bacmids' (Bac-to-Bac(R) Baculovirus Expression Systems, Invitrogen). Recombinant 'Bacmids' were purified using the High Purity Plasmid Miniprep System (Marligen), and infected to insect cells with the Cellfectin reagent according to the manufacturer's recommendation. A high-titer viral stock was obtained, and Sf9 cells were infected at a multiplicity of infection (MOI) of 10 for 72 h. Then, the cells were harvested and lysed in insect cell lysis buffer (BD Pharmingen) with 1x Complete Mini (Roche Diagnostic Corporation) for 30 min at 4degreesC. Recombinant human aprataxin was first purified by immobilized metal affinity chromatography (MagExtractor(R) His-tag protein purification kit, TOYOBO). The extracts were fractionated by gel filtration column chromatography (AKTA explorer 10S with HiLoad 16/60 Superdex 75 pg column, GE Healthcare) in 50 mM Tris-HCl (pH 7.5) and 100 mM NaCl. These fractionated extracts were desalinized using Slide-A-Lyzer(R) dialysis cassettes (Pierce Biotechnology), separated by denaturing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and stained with Coomassie brilliant blue (CBB). Western blotting was performed using an anti-Tetra-His antibody (Quiagen) and an anti-aprataxin antibody (ab31841, Abcom).
###end p 10
###begin p 11
###xml 69 80 66 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bombyx mori</italic>
###xml 412 423 409 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bombyx mori</italic>
###xml 502 513 499 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bombyx mori</italic>
###xml 12 17 <span type="species:ncbi:9606">human</span>
###xml 60 68 <span type="species:ncbi:7091">silkworm</span>
###xml 69 80 <span type="species:ncbi:7091">Bombyx mori</span>
###xml 172 177 <span type="species:ncbi:9606">Human</span>
###xml 403 411 <span type="species:ncbi:7091">silkworm</span>
###xml 412 423 <span type="species:ncbi:7091">Bombyx mori</span>
###xml 493 501 <span type="species:ncbi:7091">silkworm</span>
###xml 502 513 <span type="species:ncbi:7091">Bombyx mori</span>
Recombinant human Pol beta, PNKP and Lig3 were expressed in silkworm Bombyx mori (Katakura). The cDNA fragment of each protein was amplified by PCR using the cDNA library (Human Ovary Marathon-Ready cDNA: Clontech) as the template and then inserted into pYNGHis (Katakura). The purified plasmid vector was mixed with purified cysteine proteinase-deleted viral DNA and then cotransfected in BmN cells of silkworm Bombyx mori larvae. The obtained recombinant virus was used for the infection of silkworm Bombyx mori pupae. Infected pupae were incubated at 25degreesC, and then frozen for 144 h postinoculation. Harvested pupae were lysed, and the His-tagged protein was purified by immobilized metal affinity chromatography (MagExtractor(R) His-tag protein purification kit, TOYOBO).
###end p 11
###begin p 12
###xml 667 668 661 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 668 671 662 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600</sub>
###xml 723 724 717 718 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
Mutant aprataxin cDNAs were produced using the GeneTailer site-directed mutagenesis system (Invitrogen). Wild-type long-form aprataxin (LA) cDNA, the forkhead-associated (FHA) domain of aprataxin (1-114 amino acids; FHA), the splicing variant of aprataxin (175-343 amino acids, GenBank accession number NP_7782411; SA) and the mutant forms of aprataxin cDNA fragments were inserted into the BamHI/XhoI site of pGEX-6P-3 (GE Healthcare Bio-Science Corp.). Glutathione S-transferase (GST) fusion proteins were overexpressed in Rosetta 2 (DE3) pLysS (Novagen) bacterial cells containing these plasmids. The bacterial cells were grown at 37degreesC until they reached an A600 of 1.0 and then induced with 1 mM isopropyl-1-thio-d-galactopyranoside and grown for another 3 h before harvesting. Cell pellets were lysed using BugBuster HT (Novagen) with EDTA-free complete protease inhibitor cocktail (Sigma). The GST-tagged proteins were purified using a GST fusion protein purification kit (Bulk GST Purification Modules(R), GE Healthcare). Purified fractions were desalinized using Slide-A-Lyzer(R) dialysis cassettes (Pierce Biotechnology), separated by denaturing SDS-PAGE, and stained with CBB. Western blotting was performed using an anti-GST antibody (GE Healthcare Bio-Science Corp.) and an anti-aprataxin antibody (ab31841, Abcom).
###end p 12
###begin title 13
Oligonucleotide substrates
###end title 13
###begin p 14
###xml 1248 1249 1234 1235 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The sequences of DNA substrates used were as follows: FITC-21 (5'-[FITC]CTACGTCAGATCTGCGGATGT-3'), 21-OH (5'-CTACGTCAGATCTGCGGATGT[OH]-3'), 21-P (5'-CTACGTCAGATCTGCGGATGT[P]-3'), 24 (5'-CTCTAGCACTTGAGGCTATCCATG-3'), 23 (5'-TCTAGCACTTGAGGCTATCCATG-3'), 45 (5'-CATGGATAGCCTCAAGTGCTAGAGACATCCGCAGATCTGACGTAG-3'), FITC-21-PG (5'-[FITC]CTACGTCAGATCTGCGGATGT-[PG]-3'), FITC-21-Y (5'-[FITC]CTACGTCAGATCTGCGGATGT-[Y]-3'), and 45/21(U) (5'-[FITC]CTACGTCAGATCTGCGGATGUCTCTAGCACTTGAGGCTATCCATG-3'). 5'-FITC-labeled oligonucleotides were synthesized and purified by high-performance liquid chromatography. A 5'-FITC-labeled 3'-PG 21-mer oligonucleotide (FITC-21-PG) was obtained from Thermo Electron Corporation. A 5'-FITC-labeled 3'-phosphotyrosine 21-mer oligonucleotide (FITC-21-Y) was purchased from Midland Certified Reagent Company. A 5'-FITC-labeled 21-mer oligonucleotide with 3'-phospho-alpha, beta-unsaturated aldehyde was prepared using uracil DNA glycosylase (Invitrogen) and endonuclease III (BioLabs). To generate an apurinic/apyrimidinic (AP) site at the 21st uracil from 5', 10 muM oligonucleotide FITC-45/21(U) was incubated with uracil DNA glycosylase (2 unit) for 1 h at 37degreesC in a mixture containing 20 mM Tris-HCl (pH 8.4), 10 mM MgCl2 and 50 mM KCl. The reaction product was annealed with 10 muM oligonucleotide 45. Annealed oligonucleotides (2 muM) were treated with endonuclease III according to the manufacturer's instructions to generate the 5'-FITC-labeled 21-mer oligonucleotide with 3'-phospho-alpha, beta-unsaturated aldehyde.
###end p 14
###begin title 15
3'-End processing assay
###end title 15
###begin p 16
###xml 191 192 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 695 696 672 673 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
To analyze the activity of aprataxin to remove 3'-phosphate, 1 pmol of oligonucleotides phosphorylated at the 3'-end was incubated in a mixture containing 100 mM Tris-HCl (pH 6.0), 10 mM MgCl2, 10 mM beta-ME and 0.1 mg/ml BSA with the indicated protein (25, 50 and 100 nM aprataxin, and 50 nM PNKP) for 1 h at 37degreesC. To analyze the activity of aprataxin to remove 3'-PG, 3'-phospho-alpha, beta-unsaturated aldehyde or 3'-phosphotyrosine ends, 5'-FITC-labeled 21-mer oligonucleotides with 3'-PG, 3'-phospho-alpha, beta-unsaturated aldehyde or 3'-phosphotyrosine ends were incubated with aprataxin (25, 50 and 100 nM), APE1 and TDP1 in a mixture containing 25 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 0.5 mM ATP, 0.1 mg/ml BSA and 1 mM DTT for 1 h at 37degreesC. Reactions were stopped by adding an equal volume of gel-loading buffer (80% formamide, 10 mM EDTA and 0.1% bromophenol blue). The products were separated by electrophoresis in a denaturing 20% polyacrylamide-8 M urea gel and visualized using a Typhoon 9400 scanner (GE Healthcare). We used APE1 (TREVIGEN) and TDP1 (Abnova Corporation) as the positive controls.
###end p 16
###begin title 17
GMP- and AMP-lysine hydrolase assay
###end title 17
###begin p 18
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 454 455 446 447 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
GMP- and AMP-lysine hydrolysis assay was performed using a method originally developed for FHIT with a fluorogenic substrate, GpppBODYPY (Molecular Probes) (15). We followed the protocol of this method previously described with a slight modification. Briefly, 100 muM GpppBODYPY or ApppBODYPY was incubated with the indicated amounts of recombinant proteins (His-LA, LA, SA and FHA) for 1 h at 37degreesC in 20 mul of 20 mM Na HEPES (pH 7.0), 0.5 mM MnCl2 and 0.2 mg/ml BSA. Reactions were stopped by adding an equal volume of gel-loading buffer (80% formamide, 10 mM EDTA and 0.1% bromophenol blue). The products were separated by electrophoresis in a denaturing 20% polyacrylamide-8 M urea gel and visualized using a Typhoon 9400 scanner (GE Healthcare). We used Fhit (Upstate) as the positive control.
###end p 18
###begin title 19
Preparation of DNA 5'-adenylates
###end title 19
###begin p 20
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 467 468 464 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
DNA 5'-adenylate was essentially prepared as previously described (24). Briefly, a 12.5 muM 5'-phosphate 3'-FITC-labeled 24-mer oligonucleotide (P-24-FITC: 5'-[P]CTCTAGCACTTGAGGCTATCCATG[FITC]-3') was annealed with a 25 muM 3'-phosphate 21-mer oligonucleotide (21-P: 5'-CTACGTCAGATCTGCGGATGT[P]-3') and 25 muM complementary oligonucleotide 45. The annealed oligonucleotides were treated with 100 nM T4 DNA ligase in ligation buffer (50 mM Tris-HCl (pH7.5), 10 mM MgCl2, 5 mM DTT, 25 mug/ml BSA and 1 mM ATP) overnight at 37degreesC. Because the nick cannot be ligated owing to 3'-end blocking with phosphate, the adenylation of the 5'-end occurs as an abortive ligation intermediate. The reaction product, 5'-AMP 3'-FITC-labeled 24-mer oligonucleotide (AMP-24-FITC), was then denatured and purified by separation on a denaturing 20% polyacrylamide-8 M urea gel. Following gel extraction, AMP-24-FITC was annealed with a 3'-hydroxyl 21-mer oligonucleotide (21-OH) and oligonucleotide 45.
###end p 20
###begin title 21
DNA 5'-adenylate hydrolysis assay
###end title 21
###begin p 22
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
DNA 5'-adenylate hydrolysis assay was performed as described previously with a slight modification (25). In brief, the 45-mer duplex DNA harboring a nick with 5'-adenylate ends was incubated with aprataxin or PNKP in a mixture containing 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 5 mM DTT for the indicated times at 37degreesC. Reactions were stopped by adding an equal volume of gel-loading buffer (80% formamide, 10 mM EDTA and 0.1% bromophenol blue). The products were separated and visualized as described above.
###end p 22
###begin title 23
Reconstitution of SSBR
###end title 23
###begin p 24
###xml 176 177 176 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
For the reconstitution of DNA repair, 5'-FITC-labeled 3'-phosphate 21-mer oligonucleotides  were annealed with 45- and 23-mer oligonucleotides in a mixture containing 1 mM MgCl2, 20 mM Tris-HCl (pH 8.0) and 1 mM NaCl to form SSBs with 3'-end blocking with phosphate. The 5'-FITC-labeled 3'-hydroxyl oligonucleotide (FITC-21-OH) was used as the control of SSBs. For another DNA repair assay, FITC-21-PG oligonucleotides were annealed with 45- and 23-mer oligonucleotides to form SSBs with 3'-end blocking with PG. These substrates were incubated with Pol beta, Lig3 and aprataxin for 90 min at 37degreesC. Reaction was stopped by adding an equal volume of gel-loading buffer. The products were separated by electrophoresis in a denaturing 20% polyacrylamide-8 M urea gel and visualized using a Typhoon 9400 scanner (GE Healthcare).
###end p 24
###begin title 25
RESULTS
###end title 25
###begin title 26
Aprataxin removes 3'-phosphate and 3'-phosphoglycolate ends
###end title 26
###begin p 27
###xml 118 126 118 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 450 458 450 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 505 513 505 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 553 562 553 562 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 650 651 650 651 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 768 769 766 767 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1034 1035 1032 1033 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1264 1265 1262 1263 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1296 1297 1294 1295 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 562 1376 562 1374 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="28">Expression and purification of recombinant aprataxin in baculovirus expression system. (<bold>A</bold>) Construct of His-tagged long-form aprataxin (His-LA) expressed using Bac-to-Bac&#174; Baculovirus Expression System. (<bold>B</bold>) Chromatogram of gel-filtered aprataxin. Following immobilized metal affinity chromatography, the aprataxin-rich fraction was purified by gel filtration column chromatography. A major peak was observed for each of the fractions from 13 to 20 in the chromatogram. (<bold>C</bold>) The fractionated extracts were separated by SDS-PAGE and stained with Coomassie brilliant blue (CBB). A 39-kDa single band is detected for each of the fractions from 14 to 19. Western blot analysis using the anti-His antibody (<bold>D</bold>) and anti-aprataxin antibody (<bold>E</bold>) shows a 39-kDa immunoreactive product in each of the fractions from 13 to 21.</p>
###xml 562 1376 562 1374 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="28">Expression and purification of recombinant aprataxin in baculovirus expression system. (<bold>A</bold>) Construct of His-tagged long-form aprataxin (His-LA) expressed using Bac-to-Bac&#174; Baculovirus Expression System. (<bold>B</bold>) Chromatogram of gel-filtered aprataxin. Following immobilized metal affinity chromatography, the aprataxin-rich fraction was purified by gel filtration column chromatography. A major peak was observed for each of the fractions from 13 to 20 in the chromatogram. (<bold>C</bold>) The fractionated extracts were separated by SDS-PAGE and stained with Coomassie brilliant blue (CBB). A 39-kDa single band is detected for each of the fractions from 14 to 19. Western blot analysis using the anti-His antibody (<bold>D</bold>) and anti-aprataxin antibody (<bold>E</bold>) shows a 39-kDa immunoreactive product in each of the fractions from 13 to 21.</p></caption>
###xml 1376 1376 1374 1374 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm158f1"/>
###xml 553 1376 553 1374 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="28">Expression and purification of recombinant aprataxin in baculovirus expression system. (<bold>A</bold>) Construct of His-tagged long-form aprataxin (His-LA) expressed using Bac-to-Bac&#174; Baculovirus Expression System. (<bold>B</bold>) Chromatogram of gel-filtered aprataxin. Following immobilized metal affinity chromatography, the aprataxin-rich fraction was purified by gel filtration column chromatography. A major peak was observed for each of the fractions from 13 to 20 in the chromatogram. (<bold>C</bold>) The fractionated extracts were separated by SDS-PAGE and stained with Coomassie brilliant blue (CBB). A 39-kDa single band is detected for each of the fractions from 14 to 19. Western blot analysis using the anti-His antibody (<bold>D</bold>) and anti-aprataxin antibody (<bold>E</bold>) shows a 39-kDa immunoreactive product in each of the fractions from 13 to 21.</p></caption><graphic xlink:href="gkm158f1"/></fig>
###xml 44 49 <span type="species:ncbi:9606">human</span>
We constructed a histidine-tagged long-form human aprataxin (His-LA) using the baculovirus-protein-expression system (Figure 1A). His-LA was purified by a standard technique, followed by further purification by immobilized metal affinity and gel filtration column chromatography to remove any contamination by other proteins. A single band, which was reactive to the anti-aprataxin antibody, was observed by CBB staining for fractions from 14 to 19 (Figure 1C and E). The aprataxin-rich fraction (No. 15, Figure 1B-E) was used in the following studies. Figure 1.Expression and purification of recombinant aprataxin in baculovirus expression system. (A) Construct of His-tagged long-form aprataxin (His-LA) expressed using Bac-to-Bac(R) Baculovirus Expression System. (B) Chromatogram of gel-filtered aprataxin. Following immobilized metal affinity chromatography, the aprataxin-rich fraction was purified by gel filtration column chromatography. A major peak was observed for each of the fractions from 13 to 20 in the chromatogram. (C) The fractionated extracts were separated by SDS-PAGE and stained with Coomassie brilliant blue (CBB). A 39-kDa single band is detected for each of the fractions from 14 to 19. Western blot analysis using the anti-His antibody (D) and anti-aprataxin antibody (E) shows a 39-kDa immunoreactive product in each of the fractions from 13 to 21.
###end p 27
###begin p 28
###xml 88 89 88 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 206 207 204 205 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 472 473 470 471 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 702 703 700 701 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 734 735 732 733 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
Expression and purification of recombinant aprataxin in baculovirus expression system. (A) Construct of His-tagged long-form aprataxin (His-LA) expressed using Bac-to-Bac(R) Baculovirus Expression System. (B) Chromatogram of gel-filtered aprataxin. Following immobilized metal affinity chromatography, the aprataxin-rich fraction was purified by gel filtration column chromatography. A major peak was observed for each of the fractions from 13 to 20 in the chromatogram. (C) The fractionated extracts were separated by SDS-PAGE and stained with Coomassie brilliant blue (CBB). A 39-kDa single band is detected for each of the fractions from 14 to 19. Western blot analysis using the anti-His antibody (D) and anti-aprataxin antibody (E) shows a 39-kDa immunoreactive product in each of the fractions from 13 to 21.
###end p 28
###begin p 29
###xml 515 523 515 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 687 695 687 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 789 797 789 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 861 869 861 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1066 1074 1059 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1270 1279 1256 1265 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 1312 1313 1298 1299 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1388 1389 1374 1375 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1862 1863 1835 1836 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2273 2274 2246 2247 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2874 2875 2833 2834 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 3225 3226 3184 3185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1279 3326 1265 3285 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="30">3&#8242;-End processing by aprataxin. (<bold>A</bold>) Aprataxin removes 3&#8242;-phosphate. The 5&#8242;-FITC-labeled 3&#8242;-phosphate (3&#8242; &#8722; PO<sub>3</sub>&#8257; &#8722;) oligonucleotide was incubated in the absence (lane 2) or presence of aprataxin at different concentrations (25, 50 and 100&#8201;nM, lanes 3&#8211;5). A band with the same size as that of the 3&#8242;-hydroxyl (3&#8242;-OH) oligonucleotide (lane 1) appears in lanes with aprataxin (lanes 3&#8211;5). 5&#8242;-Polynucleotide kinase 3&#8242;-phosphatase (PNKP) was used as the positive control (lane 6). Reaction products were separated by 20% PAGE and visualized using a fluorescence gel scanner. (<bold>B</bold>) Aprataxin removes DNA 3&#8242;-phosphoglycolate. The 5&#8242;-FITC&#8211;labeled 3&#8242;-phosphoglycolate (3&#8242;-PG) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100&#8201;nM, lanes 2&#8211;4). The amount of the 3&#8242;-OH oligonucleotide increases with aprataxin concentration (lanes 2&#8211;4). Apurinic/apyrimidinic endonuclease (APE1) was used as the positive control (lane 5). (<bold>C</bold>) Aprataxin fails to remove 3&#8242;-&#945;, &#946;-unsaturated aldehyde. The 5&#8242;-FITC-labeled 3&#8242;-&#945;, &#946;-unsaturated aldehyde (3&#8242;-UA) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100&#8201;nM, lanes 2&#8211;4). The amount of the 3&#8242;-UA oligonucleotide does not decrease with increasing aprataxin concentration (lanes 2&#8211;4). The 3&#8242;-OH oligonucleotides were generated in the presence of APE1 (lane 5). The faint smear corresponding to the 3&#8242;-UA oligonucleotide in lanes 1&#8211;5 is an artifact generated under the electrophoresis conditions employed. (<bold>D</bold>) Aprataxin fails to remove 3&#8242;-phosphotyrosine end. The 5&#8242;-FITC-labeled 3&#8242;-phosphotyrosine (3&#8242;-Y) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100&#8201;nM, lanes 2&#8211;4). The amount of the 3&#8242;-Y oligonucleotide do not decrease with increasing aprataxin concentration (lanes 2&#8211;4). 3&#8242;-PO<sub>3</sub> oligonucleotides were generated in the presence of tyrosyl-DNA phosphodiesterase 1 (TDP1) (lane 5).</p>
###xml 1279 3326 1265 3285 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="30">3&#8242;-End processing by aprataxin. (<bold>A</bold>) Aprataxin removes 3&#8242;-phosphate. The 5&#8242;-FITC-labeled 3&#8242;-phosphate (3&#8242; &#8722; PO<sub>3</sub>&#8257; &#8722;) oligonucleotide was incubated in the absence (lane 2) or presence of aprataxin at different concentrations (25, 50 and 100&#8201;nM, lanes 3&#8211;5). A band with the same size as that of the 3&#8242;-hydroxyl (3&#8242;-OH) oligonucleotide (lane 1) appears in lanes with aprataxin (lanes 3&#8211;5). 5&#8242;-Polynucleotide kinase 3&#8242;-phosphatase (PNKP) was used as the positive control (lane 6). Reaction products were separated by 20% PAGE and visualized using a fluorescence gel scanner. (<bold>B</bold>) Aprataxin removes DNA 3&#8242;-phosphoglycolate. The 5&#8242;-FITC&#8211;labeled 3&#8242;-phosphoglycolate (3&#8242;-PG) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100&#8201;nM, lanes 2&#8211;4). The amount of the 3&#8242;-OH oligonucleotide increases with aprataxin concentration (lanes 2&#8211;4). Apurinic/apyrimidinic endonuclease (APE1) was used as the positive control (lane 5). (<bold>C</bold>) Aprataxin fails to remove 3&#8242;-&#945;, &#946;-unsaturated aldehyde. The 5&#8242;-FITC-labeled 3&#8242;-&#945;, &#946;-unsaturated aldehyde (3&#8242;-UA) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100&#8201;nM, lanes 2&#8211;4). The amount of the 3&#8242;-UA oligonucleotide does not decrease with increasing aprataxin concentration (lanes 2&#8211;4). The 3&#8242;-OH oligonucleotides were generated in the presence of APE1 (lane 5). The faint smear corresponding to the 3&#8242;-UA oligonucleotide in lanes 1&#8211;5 is an artifact generated under the electrophoresis conditions employed. (<bold>D</bold>) Aprataxin fails to remove 3&#8242;-phosphotyrosine end. The 5&#8242;-FITC-labeled 3&#8242;-phosphotyrosine (3&#8242;-Y) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100&#8201;nM, lanes 2&#8211;4). The amount of the 3&#8242;-Y oligonucleotide do not decrease with increasing aprataxin concentration (lanes 2&#8211;4). 3&#8242;-PO<sub>3</sub> oligonucleotides were generated in the presence of tyrosyl-DNA phosphodiesterase 1 (TDP1) (lane 5).</p></caption>
###xml 3326 3326 3285 3285 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm158f2"/>
###xml 1270 3326 1256 3285 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="30">3&#8242;-End processing by aprataxin. (<bold>A</bold>) Aprataxin removes 3&#8242;-phosphate. The 5&#8242;-FITC-labeled 3&#8242;-phosphate (3&#8242; &#8722; PO<sub>3</sub>&#8257; &#8722;) oligonucleotide was incubated in the absence (lane 2) or presence of aprataxin at different concentrations (25, 50 and 100&#8201;nM, lanes 3&#8211;5). A band with the same size as that of the 3&#8242;-hydroxyl (3&#8242;-OH) oligonucleotide (lane 1) appears in lanes with aprataxin (lanes 3&#8211;5). 5&#8242;-Polynucleotide kinase 3&#8242;-phosphatase (PNKP) was used as the positive control (lane 6). Reaction products were separated by 20% PAGE and visualized using a fluorescence gel scanner. (<bold>B</bold>) Aprataxin removes DNA 3&#8242;-phosphoglycolate. The 5&#8242;-FITC&#8211;labeled 3&#8242;-phosphoglycolate (3&#8242;-PG) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100&#8201;nM, lanes 2&#8211;4). The amount of the 3&#8242;-OH oligonucleotide increases with aprataxin concentration (lanes 2&#8211;4). Apurinic/apyrimidinic endonuclease (APE1) was used as the positive control (lane 5). (<bold>C</bold>) Aprataxin fails to remove 3&#8242;-&#945;, &#946;-unsaturated aldehyde. The 5&#8242;-FITC-labeled 3&#8242;-&#945;, &#946;-unsaturated aldehyde (3&#8242;-UA) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100&#8201;nM, lanes 2&#8211;4). The amount of the 3&#8242;-UA oligonucleotide does not decrease with increasing aprataxin concentration (lanes 2&#8211;4). The 3&#8242;-OH oligonucleotides were generated in the presence of APE1 (lane 5). The faint smear corresponding to the 3&#8242;-UA oligonucleotide in lanes 1&#8211;5 is an artifact generated under the electrophoresis conditions employed. (<bold>D</bold>) Aprataxin fails to remove 3&#8242;-phosphotyrosine end. The 5&#8242;-FITC-labeled 3&#8242;-phosphotyrosine (3&#8242;-Y) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100&#8201;nM, lanes 2&#8211;4). The amount of the 3&#8242;-Y oligonucleotide do not decrease with increasing aprataxin concentration (lanes 2&#8211;4). 3&#8242;-PO<sub>3</sub> oligonucleotides were generated in the presence of tyrosyl-DNA phosphodiesterase 1 (TDP1) (lane 5).</p></caption><graphic xlink:href="gkm158f2"/></fig>
To investigate the enzymatic activity of aprataxin against damaged 3'-ends, we examined the 3'-end processing activities of the recombinant aprataxin employing various 3'-end-modified oligonucleotides as substrates. When 3'-phosphate oligonucleotides were used as substrates, the 3'-phosphatase activity of aprataxin was clearly demonstrated by the mobility shift on a denaturing 20% polyacrylamide-8 M urea gel, in which 3'-phosphate oligonucleotides were electrophoresed faster than 3'-hydroxyl oligonucleotides (Figure 2A). By treating 3'-phosphate oligonucleotides with aprataxin, the bands corresponding to 3'-hydroxyl oligonucleotides appeared in a concentration-dependent manner (Figure 2A, lanes 3-5). Next, we determined whether aprataxin removes 3'-PG ends. Notably, as shown in Figure 2B, aprataxin removed 3'-PG ends and generated 3'-hydroxyl ends (Figure 2B). In contrast, aprataxin failed to remove 3'-alpha, beta-unsaturated aldehyde or 3'-phosphotyrosine ends under the same conditions as those in which aprataxin removed 3'-phosphate or 3'-PG ends (Figure 2C and D). These results indicate that aprataxin has 3'-end processing activities toward 3'-phosphate and 3'-PG ends, but not toward 3'-alpha, beta-unsaturated aldehyde or 3'-phosphotyrosine ends. Figure 2.3'-End processing by aprataxin. (A) Aprataxin removes 3'-phosphate. The 5'-FITC-labeled 3'-phosphate (3' - PO3insertion mark -) oligonucleotide was incubated in the absence (lane 2) or presence of aprataxin at different concentrations (25, 50 and 100 nM, lanes 3-5). A band with the same size as that of the 3'-hydroxyl (3'-OH) oligonucleotide (lane 1) appears in lanes with aprataxin (lanes 3-5). 5'-Polynucleotide kinase 3'-phosphatase (PNKP) was used as the positive control (lane 6). Reaction products were separated by 20% PAGE and visualized using a fluorescence gel scanner. (B) Aprataxin removes DNA 3'-phosphoglycolate. The 5'-FITC-labeled 3'-phosphoglycolate (3'-PG) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100 nM, lanes 2-4). The amount of the 3'-OH oligonucleotide increases with aprataxin concentration (lanes 2-4). Apurinic/apyrimidinic endonuclease (APE1) was used as the positive control (lane 5). (C) Aprataxin fails to remove 3'-alpha, beta-unsaturated aldehyde. The 5'-FITC-labeled 3'-alpha, beta-unsaturated aldehyde (3'-UA) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100 nM, lanes 2-4). The amount of the 3'-UA oligonucleotide does not decrease with increasing aprataxin concentration (lanes 2-4). The 3'-OH oligonucleotides were generated in the presence of APE1 (lane 5). The faint smear corresponding to the 3'-UA oligonucleotide in lanes 1-5 is an artifact generated under the electrophoresis conditions employed. (D) Aprataxin fails to remove 3'-phosphotyrosine end. The 5'-FITC-labeled 3'-phosphotyrosine (3'-Y) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100 nM, lanes 2-4). The amount of the 3'-Y oligonucleotide do not decrease with increasing aprataxin concentration (lanes 2-4). 3'-PO3 oligonucleotides were generated in the presence of tyrosyl-DNA phosphodiesterase 1 (TDP1) (lane 5).
###end p 29
###begin p 30
###xml 33 34 33 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 109 110 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 583 584 570 571 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 994 995 981 982 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1595 1596 1568 1569 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1946 1947 1919 1920 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
3'-End processing by aprataxin. (A) Aprataxin removes 3'-phosphate. The 5'-FITC-labeled 3'-phosphate (3' - PO3insertion mark -) oligonucleotide was incubated in the absence (lane 2) or presence of aprataxin at different concentrations (25, 50 and 100 nM, lanes 3-5). A band with the same size as that of the 3'-hydroxyl (3'-OH) oligonucleotide (lane 1) appears in lanes with aprataxin (lanes 3-5). 5'-Polynucleotide kinase 3'-phosphatase (PNKP) was used as the positive control (lane 6). Reaction products were separated by 20% PAGE and visualized using a fluorescence gel scanner. (B) Aprataxin removes DNA 3'-phosphoglycolate. The 5'-FITC-labeled 3'-phosphoglycolate (3'-PG) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100 nM, lanes 2-4). The amount of the 3'-OH oligonucleotide increases with aprataxin concentration (lanes 2-4). Apurinic/apyrimidinic endonuclease (APE1) was used as the positive control (lane 5). (C) Aprataxin fails to remove 3'-alpha, beta-unsaturated aldehyde. The 5'-FITC-labeled 3'-alpha, beta-unsaturated aldehyde (3'-UA) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100 nM, lanes 2-4). The amount of the 3'-UA oligonucleotide does not decrease with increasing aprataxin concentration (lanes 2-4). The 3'-OH oligonucleotides were generated in the presence of APE1 (lane 5). The faint smear corresponding to the 3'-UA oligonucleotide in lanes 1-5 is an artifact generated under the electrophoresis conditions employed. (D) Aprataxin fails to remove 3'-phosphotyrosine end. The 5'-FITC-labeled 3'-phosphotyrosine (3'-Y) oligonucleotide was incubated in the absence (lane 1) or presence of aprataxin at different concentrations (25, 50 and 100 nM, lanes 2-4). The amount of the 3'-Y oligonucleotide do not decrease with increasing aprataxin concentration (lanes 2-4). 3'-PO3 oligonucleotides were generated in the presence of tyrosyl-DNA phosphodiesterase 1 (TDP1) (lane 5).
###end p 30
###begin title 31
FHA domain of aprataxin and disease-associated mutant forms of aprataxin lack 3'-phosphatase and 3'-phosphoglycolate hydrolase activities
###end title 31
###begin p 32
###xml 506 514 506 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 524 525 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 700 708 700 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 762 770 762 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 863 871 863 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 881 890 881 890 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 947 948 947 948 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1259 1260 1259 1260 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 890 1715 890 1715 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="33">Expression of recombinant GST-aprataxin fusion protein. (<bold>A</bold>) Constructs of GST-aprataxin fusion proteins. Constructs of GST fusion protein containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the N-terminal FHA domain of aprataxin (FHA) and full-length aprataxin with P206L or V263G (P206L, V263G). (<bold>B</bold>) Expression and purification of GST-aprataxin fusion proteins. Recombinant GST fusion proteins containing LA (lanes 1, 6 and 11), SA (lanes 2, 7 and 12), FHA (lanes 3, 8 and 13), P206L (lanes 4, 9 and 14) and V263G (lanes 5, 10 and 15) were expressed in the bacterial expression system. Purified products were analyzed by CBB staining (left panel), and western blotting using the anti-GST antibody (middle panel) or anti-aprataxin antibody (right panel).</p>
###xml 890 1715 890 1715 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="33">Expression of recombinant GST-aprataxin fusion protein. (<bold>A</bold>) Constructs of GST-aprataxin fusion proteins. Constructs of GST fusion protein containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the N-terminal FHA domain of aprataxin (FHA) and full-length aprataxin with P206L or V263G (P206L, V263G). (<bold>B</bold>) Expression and purification of GST-aprataxin fusion proteins. Recombinant GST fusion proteins containing LA (lanes 1, 6 and 11), SA (lanes 2, 7 and 12), FHA (lanes 3, 8 and 13), P206L (lanes 4, 9 and 14) and V263G (lanes 5, 10 and 15) were expressed in the bacterial expression system. Purified products were analyzed by CBB staining (left panel), and western blotting using the anti-GST antibody (middle panel) or anti-aprataxin antibody (right panel).</p></caption>
###xml 1715 1715 1715 1715 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm158f3"/>
###xml 881 1715 881 1715 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="33">Expression of recombinant GST-aprataxin fusion protein. (<bold>A</bold>) Constructs of GST-aprataxin fusion proteins. Constructs of GST fusion protein containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the N-terminal FHA domain of aprataxin (FHA) and full-length aprataxin with P206L or V263G (P206L, V263G). (<bold>B</bold>) Expression and purification of GST-aprataxin fusion proteins. Recombinant GST fusion proteins containing LA (lanes 1, 6 and 11), SA (lanes 2, 7 and 12), FHA (lanes 3, 8 and 13), P206L (lanes 4, 9 and 14) and V263G (lanes 5, 10 and 15) were expressed in the bacterial expression system. Purified products were analyzed by CBB staining (left panel), and western blotting using the anti-GST antibody (middle panel) or anti-aprataxin antibody (right panel).</p></caption><graphic xlink:href="gkm158f3"/></fig>
###xml 1715 1724 1715 1724 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 1809 1810 1809 1810 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1908 1909 1908 1909 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 2433 2434 2420 2421 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1724 3003 1724 2990 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="34">Disease-associated mutant forms of aprataxin lack their 3&#8242;-end processing activity. (<bold>A</bold>) Mutant forms of aprataxin fail to remove 3&#8242;-phosphate. The 5&#8242;-FITC-labeled 3&#8242;-phosphate (3&#8242; &#8722; PO<sub>3</sub>&#8257; &#8722;) oligonucleotide was incubated in the presence of 50&#8201;nM recombinant GST fusion proteins containing LA (lanes 2&#8211;4), SA (lanes 5&#8211;7), FHA (lanes 8&#8211;10), P206L (lanes 11&#8211;13), and V263G (lanes 14&#8211;16) at different incubation times (0, 30 and 60&#8201;min). A band of the same size as that corresponding to the 3&#8242;-hydroxyl (3&#8242;-OH) oligonucleotide (lane 1) appears in lanes with LA (lanes 3 and 4). SA showed a weak phosphatase activity (lanes 5&#8211;7). Neither FHA, P206L nor V263G showed phosphatase activity (lanes 8&#8211;16). (<bold>B</bold>) Mutant forms of aprataxin fail to remove 3&#8242;-phosphoglycolate. The 5&#8242;-FITC-labeled 3&#8242;-PG oligonucleotide was incubated in the presence of 50&#8201;nM recombinant GST fusion proteins containing LA (lanes 3&#8211;5), SA (lanes 6&#8211;8), FHA (lanes 9&#8211;11), P206L (lanes 12&#8211;14) and V263G (lanes 15&#8211;17) at different incubation times (0, 30 and 60&#8201;min). A band of the same size as that corresponding to the 3&#8242;-OH oligonucleotide (lane 2) appears in lanes with LA (lanes 3 and 4). SA showed a weak 3&#8242;-PG hydrolase activity (lanes 6&#8211;8). Neither FHA, P206L nor V263G removed 3&#8242;-PG (lanes 9&#8211;17).</p>
###xml 1724 3003 1724 2990 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="34">Disease-associated mutant forms of aprataxin lack their 3&#8242;-end processing activity. (<bold>A</bold>) Mutant forms of aprataxin fail to remove 3&#8242;-phosphate. The 5&#8242;-FITC-labeled 3&#8242;-phosphate (3&#8242; &#8722; PO<sub>3</sub>&#8257; &#8722;) oligonucleotide was incubated in the presence of 50&#8201;nM recombinant GST fusion proteins containing LA (lanes 2&#8211;4), SA (lanes 5&#8211;7), FHA (lanes 8&#8211;10), P206L (lanes 11&#8211;13), and V263G (lanes 14&#8211;16) at different incubation times (0, 30 and 60&#8201;min). A band of the same size as that corresponding to the 3&#8242;-hydroxyl (3&#8242;-OH) oligonucleotide (lane 1) appears in lanes with LA (lanes 3 and 4). SA showed a weak phosphatase activity (lanes 5&#8211;7). Neither FHA, P206L nor V263G showed phosphatase activity (lanes 8&#8211;16). (<bold>B</bold>) Mutant forms of aprataxin fail to remove 3&#8242;-phosphoglycolate. The 5&#8242;-FITC-labeled 3&#8242;-PG oligonucleotide was incubated in the presence of 50&#8201;nM recombinant GST fusion proteins containing LA (lanes 3&#8211;5), SA (lanes 6&#8211;8), FHA (lanes 9&#8211;11), P206L (lanes 12&#8211;14) and V263G (lanes 15&#8211;17) at different incubation times (0, 30 and 60&#8201;min). A band of the same size as that corresponding to the 3&#8242;-OH oligonucleotide (lane 2) appears in lanes with LA (lanes 3 and 4). SA showed a weak 3&#8242;-PG hydrolase activity (lanes 6&#8211;8). Neither FHA, P206L nor V263G removed 3&#8242;-PG (lanes 9&#8211;17).</p></caption>
###xml 3003 3003 2990 2990 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm158f4"/>
###xml 1715 3003 1715 2990 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="34">Disease-associated mutant forms of aprataxin lack their 3&#8242;-end processing activity. (<bold>A</bold>) Mutant forms of aprataxin fail to remove 3&#8242;-phosphate. The 5&#8242;-FITC-labeled 3&#8242;-phosphate (3&#8242; &#8722; PO<sub>3</sub>&#8257; &#8722;) oligonucleotide was incubated in the presence of 50&#8201;nM recombinant GST fusion proteins containing LA (lanes 2&#8211;4), SA (lanes 5&#8211;7), FHA (lanes 8&#8211;10), P206L (lanes 11&#8211;13), and V263G (lanes 14&#8211;16) at different incubation times (0, 30 and 60&#8201;min). A band of the same size as that corresponding to the 3&#8242;-hydroxyl (3&#8242;-OH) oligonucleotide (lane 1) appears in lanes with LA (lanes 3 and 4). SA showed a weak phosphatase activity (lanes 5&#8211;7). Neither FHA, P206L nor V263G showed phosphatase activity (lanes 8&#8211;16). (<bold>B</bold>) Mutant forms of aprataxin fail to remove 3&#8242;-phosphoglycolate. The 5&#8242;-FITC-labeled 3&#8242;-PG oligonucleotide was incubated in the presence of 50&#8201;nM recombinant GST fusion proteins containing LA (lanes 3&#8211;5), SA (lanes 6&#8211;8), FHA (lanes 9&#8211;11), P206L (lanes 12&#8211;14) and V263G (lanes 15&#8211;17) at different incubation times (0, 30 and 60&#8201;min). A band of the same size as that corresponding to the 3&#8242;-OH oligonucleotide (lane 2) appears in lanes with LA (lanes 3 and 4). SA showed a weak 3&#8242;-PG hydrolase activity (lanes 6&#8211;8). Neither FHA, P206L nor V263G removed 3&#8242;-PG (lanes 9&#8211;17).</p></caption><graphic xlink:href="gkm158f4"/></fig>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
To confirm the 3'-phosphatase and 3'-PG hydrolase activities and determine the catalytic domain of aprataxin, we constructed five types of the aprataxin fusion protein including wild-type full-length aprataxin (long-form aprataxin, LA), two types of full-length mutant form of aprataxin (P206L and V263G), which are most frequently found in Japanese patients, the N-terminal FHA domain (FHA) of aprataxin, and aprataxin without the FHA domain (short-form aprataxin, SA) in the bacterial expression system (Figure 3A and B) (1). The GST-tagged long-form aprataxin (LA) showed 3'-phosphatase and 3'-PG hydrolase activities comparable to those of His-LA obtained from the baculovirus expression system (Figure 4A and B). Although SA removed 3'-phosphate and 3'-PG (Figure 4A and B), its removal activity was lower than that of LA. FHA did not show removal activity (Figure 4A and B). Figure 3.Expression of recombinant GST-aprataxin fusion protein. (A) Constructs of GST-aprataxin fusion proteins. Constructs of GST fusion protein containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the N-terminal FHA domain of aprataxin (FHA) and full-length aprataxin with P206L or V263G (P206L, V263G). (B) Expression and purification of GST-aprataxin fusion proteins. Recombinant GST fusion proteins containing LA (lanes 1, 6 and 11), SA (lanes 2, 7 and 12), FHA (lanes 3, 8 and 13), P206L (lanes 4, 9 and 14) and V263G (lanes 5, 10 and 15) were expressed in the bacterial expression system. Purified products were analyzed by CBB staining (left panel), and western blotting using the anti-GST antibody (middle panel) or anti-aprataxin antibody (right panel).Figure 4.Disease-associated mutant forms of aprataxin lack their 3'-end processing activity. (A) Mutant forms of aprataxin fail to remove 3'-phosphate. The 5'-FITC-labeled 3'-phosphate (3' - PO3insertion mark -) oligonucleotide was incubated in the presence of 50 nM recombinant GST fusion proteins containing LA (lanes 2-4), SA (lanes 5-7), FHA (lanes 8-10), P206L (lanes 11-13), and V263G (lanes 14-16) at different incubation times (0, 30 and 60 min). A band of the same size as that corresponding to the 3'-hydroxyl (3'-OH) oligonucleotide (lane 1) appears in lanes with LA (lanes 3 and 4). SA showed a weak phosphatase activity (lanes 5-7). Neither FHA, P206L nor V263G showed phosphatase activity (lanes 8-16). (B) Mutant forms of aprataxin fail to remove 3'-phosphoglycolate. The 5'-FITC-labeled 3'-PG oligonucleotide was incubated in the presence of 50 nM recombinant GST fusion proteins containing LA (lanes 3-5), SA (lanes 6-8), FHA (lanes 9-11), P206L (lanes 12-14) and V263G (lanes 15-17) at different incubation times (0, 30 and 60 min). A band of the same size as that corresponding to the 3'-OH oligonucleotide (lane 2) appears in lanes with LA (lanes 3 and 4). SA showed a weak 3'-PG hydrolase activity (lanes 6-8). Neither FHA, P206L nor V263G removed 3'-PG (lanes 9-17).
###end p 32
###begin p 33
###xml 57 58 57 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 369 370 369 370 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Expression of recombinant GST-aprataxin fusion protein. (A) Constructs of GST-aprataxin fusion proteins. Constructs of GST fusion protein containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the N-terminal FHA domain of aprataxin (FHA) and full-length aprataxin with P206L or V263G (P206L, V263G). (B) Expression and purification of GST-aprataxin fusion proteins. Recombinant GST fusion proteins containing LA (lanes 1, 6 and 11), SA (lanes 2, 7 and 12), FHA (lanes 3, 8 and 13), P206L (lanes 4, 9 and 14) and V263G (lanes 5, 10 and 15) were expressed in the bacterial expression system. Purified products were analyzed by CBB staining (left panel), and western blotting using the anti-GST antibody (middle panel) or anti-aprataxin antibody (right panel).
###end p 33
###begin p 34
###xml 85 86 85 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 184 185 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 709 710 696 697 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Disease-associated mutant forms of aprataxin lack their 3'-end processing activity. (A) Mutant forms of aprataxin fail to remove 3'-phosphate. The 5'-FITC-labeled 3'-phosphate (3' - PO3insertion mark -) oligonucleotide was incubated in the presence of 50 nM recombinant GST fusion proteins containing LA (lanes 2-4), SA (lanes 5-7), FHA (lanes 8-10), P206L (lanes 11-13), and V263G (lanes 14-16) at different incubation times (0, 30 and 60 min). A band of the same size as that corresponding to the 3'-hydroxyl (3'-OH) oligonucleotide (lane 1) appears in lanes with LA (lanes 3 and 4). SA showed a weak phosphatase activity (lanes 5-7). Neither FHA, P206L nor V263G showed phosphatase activity (lanes 8-16). (B) Mutant forms of aprataxin fail to remove 3'-phosphoglycolate. The 5'-FITC-labeled 3'-PG oligonucleotide was incubated in the presence of 50 nM recombinant GST fusion proteins containing LA (lanes 3-5), SA (lanes 6-8), FHA (lanes 9-11), P206L (lanes 12-14) and V263G (lanes 15-17) at different incubation times (0, 30 and 60 min). A band of the same size as that corresponding to the 3'-OH oligonucleotide (lane 2) appears in lanes with LA (lanes 3 and 4). SA showed a weak 3'-PG hydrolase activity (lanes 6-8). Neither FHA, P206L nor V263G removed 3'-PG (lanes 9-17).
###end p 34
###begin p 35
###xml 205 213 205 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 364 365 340 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 440 448 416 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
Next, we examined whether mutant forms of aprataxin remove 3'-phosphate and 3'-PG ends. Although the mutant aprataxin proteins were unstable, we were able to produce full-length mutant forms of aprataxin (Figure 3B). These purified mutant proteins contained a approximately63 kDa form, that is, full-length aprataxin and a approximately46 kDa form that retained NH2-terminal GST. Neither P206L nor V263G removed 3'-phosphate or 3'-PG ends (Figure 4A and B).
###end p 35
###begin p 36
###xml 102 109 102 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 503 511 503 511 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1.</label>
###xml 511 648 511 648 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="37">Enzymatic activity of recombinant forms of aprataxin determined using 3&#8242;-phosphate and 3&#8242;-phosphoglycolate oligonucleotides as substrates</p>
###xml 511 648 511 648 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="37">Enzymatic activity of recombinant forms of aprataxin determined using 3&#8242;-phosphate and 3&#8242;-phosphoglycolate oligonucleotides as substrates</p></caption>
###xml 648 648 648 648 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 648 650 648 650 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">LA</th>
###xml 650 652 650 652 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">SA</th>
###xml 652 655 652 655 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">FHA</th>
###xml 655 660 655 660 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">P206L</th>
###xml 660 665 660 665 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">V263G</th>
###xml 665 669 665 669 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">PNKP</th>
###xml 669 673 669 673 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">APE1</th>
###xml 648 673 648 673 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">LA</th><th rowspan="1" colspan="1">SA</th><th rowspan="1" colspan="1">FHA</th><th rowspan="1" colspan="1">P206L</th><th rowspan="1" colspan="1">V263G</th><th rowspan="1" colspan="1">PNKP</th><th rowspan="1" colspan="1">APE1</th></tr>
###xml 648 673 648 673 <thead xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">LA</th><th rowspan="1" colspan="1">SA</th><th rowspan="1" colspan="1">FHA</th><th rowspan="1" colspan="1">P206L</th><th rowspan="1" colspan="1">V263G</th><th rowspan="1" colspan="1">PNKP</th><th rowspan="1" colspan="1">APE1</th></tr></thead>
###xml 673 685 673 685 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" colspan="8" rowspan="1">3&#8242;-Phosphate</td>
###xml 673 685 673 685 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td colspan="8" rowspan="1">3&#8242;-Phosphate</td></tr>
###xml 685 686 685 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 686 689 686 689 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cat</sub>
###xml 692 694 692 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 685 695 685 695 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>K</italic><sub>cat</sub> (s<sup>&#8722;1</sup>)</td>
###xml 695 714 695 712 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.00027&#8201;&#177;&#8201;0.00007</td>
###xml 714 733 712 729 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.00015&#8201;&#177;&#8201;0.00001</td>
###xml 733 741 729 737 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&lt;0.00002</td>
###xml 741 749 737 745 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&lt;0.00002</td>
###xml 749 757 745 753 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&lt;0.00002</td>
###xml 757 776 753 770 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.00262&#8201;&#177;&#8201;0.00022</td>
###xml 776 776 770 770 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 685 776 685 770 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>K</italic><sub>cat</sub> (s<sup>&#8722;1</sup>)</td><td rowspan="1" colspan="1">0.00027&#8201;&#177;&#8201;0.00007</td><td rowspan="1" colspan="1">0.00015&#8201;&#177;&#8201;0.00001</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">0.00262&#8201;&#177;&#8201;0.00022</td><td rowspan="1" colspan="1"/></tr>
###xml 776 777 770 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 777 778 771 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 776 783 770 777 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>K</italic><sub>m</sub> (nM)</td>
###xml 783 793 777 785 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">129&#8201;&#177;&#8201;76</td>
###xml 793 803 785 793 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">251&#8201;&#177;&#8201;58</td>
###xml 803 803 793 793 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 803 803 793 793 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 803 803 793 793 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 803 814 793 802 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">228&#8201;&#177;&#8201;124</td>
###xml 814 814 802 802 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 776 814 770 802 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>K</italic><sub>m</sub> (nM)</td><td rowspan="1" colspan="1">129&#8201;&#177;&#8201;76</td><td rowspan="1" colspan="1">251&#8201;&#177;&#8201;58</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">228&#8201;&#177;&#8201;124</td><td rowspan="1" colspan="1"/></tr>
###xml 814 833 802 821 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" colspan="8" rowspan="1">3&#8242;-Phosphoglycolate</td>
###xml 814 833 802 821 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td colspan="8" rowspan="1">3&#8242;-Phosphoglycolate</td></tr>
###xml 833 834 821 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 834 837 822 825 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cat</sub>
###xml 840 842 828 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 833 843 821 831 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>K</italic><sub>cat</sub> (s<sup>&#8722;1</sup>)</td>
###xml 843 862 831 848 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.00287&#8201;&#177;&#8201;0.00039</td>
###xml 862 881 848 865 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.00160&#8201;&#177;&#8201;0.00009</td>
###xml 881 889 865 873 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&lt;0.00002</td>
###xml 889 897 873 881 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&lt;0.00002</td>
###xml 897 905 881 889 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&lt;0.00002</td>
###xml 905 905 889 889 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 905 924 889 906 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.00014&#8201;&#177;&#8201;0.00001</td>
###xml 833 924 821 906 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>K</italic><sub>cat</sub> (s<sup>&#8722;1</sup>)</td><td rowspan="1" colspan="1">0.00287&#8201;&#177;&#8201;0.00039</td><td rowspan="1" colspan="1">0.00160&#8201;&#177;&#8201;0.00009</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.00014&#8201;&#177;&#8201;0.00001</td></tr>
###xml 924 925 906 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 925 926 907 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 924 931 906 913 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>K</italic><sub>m</sub> (nM)</td>
###xml 931 941 913 921 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">231&#8201;&#177;&#8201;37</td>
###xml 941 951 921 929 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">292&#8201;&#177;&#8201;31</td>
###xml 951 951 929 929 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 951 951 929 929 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 951 951 929 929 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 951 951 929 929 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 951 960 929 936 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">61&#8201;&#177;&#8201;28</td>
###xml 924 960 906 936 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>K</italic><sub>m</sub> (nM)</td><td rowspan="1" colspan="1">231&#8201;&#177;&#8201;37</td><td rowspan="1" colspan="1">292&#8201;&#177;&#8201;31</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">61&#8201;&#177;&#8201;28</td></tr>
###xml 673 960 673 936 <tbody xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><td colspan="8" rowspan="1">3&#8242;-Phosphate</td></tr><tr><td rowspan="1" colspan="1"><italic>K</italic><sub>cat</sub> (s<sup>&#8722;1</sup>)</td><td rowspan="1" colspan="1">0.00027&#8201;&#177;&#8201;0.00007</td><td rowspan="1" colspan="1">0.00015&#8201;&#177;&#8201;0.00001</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">0.00262&#8201;&#177;&#8201;0.00022</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>K</italic><sub>m</sub> (nM)</td><td rowspan="1" colspan="1">129&#8201;&#177;&#8201;76</td><td rowspan="1" colspan="1">251&#8201;&#177;&#8201;58</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">228&#8201;&#177;&#8201;124</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="8" rowspan="1">3&#8242;-Phosphoglycolate</td></tr><tr><td rowspan="1" colspan="1"><italic>K</italic><sub>cat</sub> (s<sup>&#8722;1</sup>)</td><td rowspan="1" colspan="1">0.00287&#8201;&#177;&#8201;0.00039</td><td rowspan="1" colspan="1">0.00160&#8201;&#177;&#8201;0.00009</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.00014&#8201;&#177;&#8201;0.00001</td></tr><tr><td rowspan="1" colspan="1"><italic>K</italic><sub>m</sub> (nM)</td><td rowspan="1" colspan="1">231&#8201;&#177;&#8201;37</td><td rowspan="1" colspan="1">292&#8201;&#177;&#8201;31</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">61&#8201;&#177;&#8201;28</td></tr></tbody>
###xml 648 960 648 936 <table xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">LA</th><th rowspan="1" colspan="1">SA</th><th rowspan="1" colspan="1">FHA</th><th rowspan="1" colspan="1">P206L</th><th rowspan="1" colspan="1">V263G</th><th rowspan="1" colspan="1">PNKP</th><th rowspan="1" colspan="1">APE1</th></tr></thead><tbody align="left"><tr><td colspan="8" rowspan="1">3&#8242;-Phosphate</td></tr><tr><td rowspan="1" colspan="1"><italic>K</italic><sub>cat</sub> (s<sup>&#8722;1</sup>)</td><td rowspan="1" colspan="1">0.00027&#8201;&#177;&#8201;0.00007</td><td rowspan="1" colspan="1">0.00015&#8201;&#177;&#8201;0.00001</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">0.00262&#8201;&#177;&#8201;0.00022</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>K</italic><sub>m</sub> (nM)</td><td rowspan="1" colspan="1">129&#8201;&#177;&#8201;76</td><td rowspan="1" colspan="1">251&#8201;&#177;&#8201;58</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">228&#8201;&#177;&#8201;124</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="8" rowspan="1">3&#8242;-Phosphoglycolate</td></tr><tr><td rowspan="1" colspan="1"><italic>K</italic><sub>cat</sub> (s<sup>&#8722;1</sup>)</td><td rowspan="1" colspan="1">0.00287&#8201;&#177;&#8201;0.00039</td><td rowspan="1" colspan="1">0.00160&#8201;&#177;&#8201;0.00009</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.00014&#8201;&#177;&#8201;0.00001</td></tr><tr><td rowspan="1" colspan="1"><italic>K</italic><sub>m</sub> (nM)</td><td rowspan="1" colspan="1">231&#8201;&#177;&#8201;37</td><td rowspan="1" colspan="1">292&#8201;&#177;&#8201;31</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">61&#8201;&#177;&#8201;28</td></tr></tbody></table>
###xml 960 1245 936 1221 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="38">GST fusion proteins containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the N-terminal FHA domain of aprataxin (FHA), full-length aprataxin with P206L (P206L) and full-length aprataxin with V263G (V263G) were used.</p>
###xml 960 1245 936 1221 <fn xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="38">GST fusion proteins containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the N-terminal FHA domain of aprataxin (FHA), full-length aprataxin with P206L (P206L) and full-length aprataxin with V263G (V263G) were used.</p></fn>
###xml 960 1245 936 1221 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><fn><p textid="38">GST fusion proteins containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the N-terminal FHA domain of aprataxin (FHA), full-length aprataxin with P206L (P206L) and full-length aprataxin with V263G (V263G) were used.</p></fn></table-wrap-foot>
###xml 503 1245 503 1221 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T1" position="float"><label>Table 1.</label><caption><p textid="37">Enzymatic activity of recombinant forms of aprataxin determined using 3&#8242;-phosphate and 3&#8242;-phosphoglycolate oligonucleotides as substrates</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">LA</th><th rowspan="1" colspan="1">SA</th><th rowspan="1" colspan="1">FHA</th><th rowspan="1" colspan="1">P206L</th><th rowspan="1" colspan="1">V263G</th><th rowspan="1" colspan="1">PNKP</th><th rowspan="1" colspan="1">APE1</th></tr></thead><tbody align="left"><tr><td colspan="8" rowspan="1">3&#8242;-Phosphate</td></tr><tr><td rowspan="1" colspan="1"><italic>K</italic><sub>cat</sub> (s<sup>&#8722;1</sup>)</td><td rowspan="1" colspan="1">0.00027&#8201;&#177;&#8201;0.00007</td><td rowspan="1" colspan="1">0.00015&#8201;&#177;&#8201;0.00001</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">0.00262&#8201;&#177;&#8201;0.00022</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>K</italic><sub>m</sub> (nM)</td><td rowspan="1" colspan="1">129&#8201;&#177;&#8201;76</td><td rowspan="1" colspan="1">251&#8201;&#177;&#8201;58</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">228&#8201;&#177;&#8201;124</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="8" rowspan="1">3&#8242;-Phosphoglycolate</td></tr><tr><td rowspan="1" colspan="1"><italic>K</italic><sub>cat</sub> (s<sup>&#8722;1</sup>)</td><td rowspan="1" colspan="1">0.00287&#8201;&#177;&#8201;0.00039</td><td rowspan="1" colspan="1">0.00160&#8201;&#177;&#8201;0.00009</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1">&lt;0.00002</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.00014&#8201;&#177;&#8201;0.00001</td></tr><tr><td rowspan="1" colspan="1"><italic>K</italic><sub>m</sub> (nM)</td><td rowspan="1" colspan="1">231&#8201;&#177;&#8201;37</td><td rowspan="1" colspan="1">292&#8201;&#177;&#8201;31</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">61&#8201;&#177;&#8201;28</td></tr></tbody></table><table-wrap-foot><fn><p textid="38">GST fusion proteins containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the N-terminal FHA domain of aprataxin (FHA), full-length aprataxin with P206L (P206L) and full-length aprataxin with V263G (V263G) were used.</p></fn></table-wrap-foot></table-wrap>
The affinity and catalytic activity of these aprataxin proteins for these two substrates are shown in Table 1. LA showed the highest 3'-phosphatase and 3'-PG hydrolase activities, whereas SA showed the activities less than one-half of those of LA. FHA, P206L and V263G lacked the activities. These results indicate that the C-terminal region of aprataxin, which includes the HIT motif, is indispensable for these activities and the N-terminal region of 1-174 amino acids might enhance these activities. Table 1.Enzymatic activity of recombinant forms of aprataxin determined using 3'-phosphate and 3'-phosphoglycolate oligonucleotides as substratesLASAFHAP206LV263GPNKPAPE13'-PhosphateKcat (s-1)0.00027 +/- 0.000070.00015 +/- 0.00001<0.00002<0.00002<0.000020.00262 +/- 0.00022Km (nM)129 +/- 76251 +/- 58228 +/- 1243'-PhosphoglycolateKcat (s-1)0.00287 +/- 0.000390.00160 +/- 0.00009<0.00002<0.00002<0.000020.00014 +/- 0.00001Km (nM)231 +/- 37292 +/- 3161 +/- 28GST fusion proteins containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the N-terminal FHA domain of aprataxin (FHA), full-length aprataxin with P206L (P206L) and full-length aprataxin with V263G (V263G) were used.
###end p 36
###begin p 37
Enzymatic activity of recombinant forms of aprataxin determined using 3'-phosphate and 3'-phosphoglycolate oligonucleotides as substrates
###end p 37
###begin p 38
GST fusion proteins containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the N-terminal FHA domain of aprataxin (FHA), full-length aprataxin with P206L (P206L) and full-length aprataxin with V263G (V263G) were used.
###end p 38
###begin p 39
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 109 112 109 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cat</sub>
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 201 204 201 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cat</sub>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 311 318 311 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 344 345 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 345 348 345 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cat</sub>
We compared these activities of LA with those of PNKP or APE1 in parallel experiments. The turnover number (Kcat) of the 3'-phosphatase activity of LA was 10-fold lower than that of PNKP, whereas the Kcat of the 3'-phosphatase activity of PNKP under our conditions was lower than that previously reported (23) (Table 1). On the other hand, the Kcat of the 3'-PG hydrolase activity of LA was approximately20-fold higher than that of APE1.
###end p 39
###begin title 40
Substrate specificity of aprataxin
###end title 40
###begin p 41
###xml 189 197 189 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 316 324 316 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 482 490 482 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 496 505 496 505 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 574 577 574 577 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;C</bold>
###xml 1193 1196 1187 1190 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D&#8211;F</bold>
###xml 505 1616 505 1604 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="42">Aprataxin 3&#8242;-end processing activities on ss and ds DNA substrates. (<bold>A&#8211;C</bold>) 3&#8242;-Phosphatase activity of aprataxin on ss and ds DNA substrates. (A) The ss, recessed, one-nucleotide gapped and nicked DNA substrates with 3&#8242;-phosphate ends used are shown schematically. (B) Aprataxin preferentially acts on ss DNA. The substrates were incubated with 20&#8201;nM LA for the indicated times (0, 30, 60 and 90&#8201;min) at 37&#176;C. Products were separated by denaturing PAGE and visualized using a Typhoon 9400 scanner (GE Healthcare). (C) Production rates in each reaction were quantified by ImageQuant TL (GE Healthcare). Error bars indicate standard errors for more than three independent experiments. (<bold>D&#8211;F</bold>) 3&#8242;-PG hydrolase activity of aprataxin on ss and ds DNA substrates. (D) The ss, recessed, one-nucleotide gapped and nicked DNA substrates with 3&#8242;-PG ends used are shown schematically. (E) Aprataxin preferentially acts on ss and gapped DNA. The substrates were incubated with 20&#8201;nM LA for the indicated times (0, 30, 60 and 90&#8201;min) at 37&#176;C. (F) Production rates in each reaction were quantified as described above.</p>
###xml 505 1616 505 1604 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="42">Aprataxin 3&#8242;-end processing activities on ss and ds DNA substrates. (<bold>A&#8211;C</bold>) 3&#8242;-Phosphatase activity of aprataxin on ss and ds DNA substrates. (A) The ss, recessed, one-nucleotide gapped and nicked DNA substrates with 3&#8242;-phosphate ends used are shown schematically. (B) Aprataxin preferentially acts on ss DNA. The substrates were incubated with 20&#8201;nM LA for the indicated times (0, 30, 60 and 90&#8201;min) at 37&#176;C. Products were separated by denaturing PAGE and visualized using a Typhoon 9400 scanner (GE Healthcare). (C) Production rates in each reaction were quantified by ImageQuant TL (GE Healthcare). Error bars indicate standard errors for more than three independent experiments. (<bold>D&#8211;F</bold>) 3&#8242;-PG hydrolase activity of aprataxin on ss and ds DNA substrates. (D) The ss, recessed, one-nucleotide gapped and nicked DNA substrates with 3&#8242;-PG ends used are shown schematically. (E) Aprataxin preferentially acts on ss and gapped DNA. The substrates were incubated with 20&#8201;nM LA for the indicated times (0, 30, 60 and 90&#8201;min) at 37&#176;C. (F) Production rates in each reaction were quantified as described above.</p></caption>
###xml 1616 1616 1604 1604 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm158f5"/>
###xml 496 1616 496 1604 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="42">Aprataxin 3&#8242;-end processing activities on ss and ds DNA substrates. (<bold>A&#8211;C</bold>) 3&#8242;-Phosphatase activity of aprataxin on ss and ds DNA substrates. (A) The ss, recessed, one-nucleotide gapped and nicked DNA substrates with 3&#8242;-phosphate ends used are shown schematically. (B) Aprataxin preferentially acts on ss DNA. The substrates were incubated with 20&#8201;nM LA for the indicated times (0, 30, 60 and 90&#8201;min) at 37&#176;C. Products were separated by denaturing PAGE and visualized using a Typhoon 9400 scanner (GE Healthcare). (C) Production rates in each reaction were quantified by ImageQuant TL (GE Healthcare). Error bars indicate standard errors for more than three independent experiments. (<bold>D&#8211;F</bold>) 3&#8242;-PG hydrolase activity of aprataxin on ss and ds DNA substrates. (D) The ss, recessed, one-nucleotide gapped and nicked DNA substrates with 3&#8242;-PG ends used are shown schematically. (E) Aprataxin preferentially acts on ss and gapped DNA. The substrates were incubated with 20&#8201;nM LA for the indicated times (0, 30, 60 and 90&#8201;min) at 37&#176;C. (F) Production rates in each reaction were quantified as described above.</p></caption><graphic xlink:href="gkm158f5"/></fig>
To investigate the substrate specificity of aprataxin, we compared the DNA 3'-phosphatase and 3'-PG hydrolase activities of aprataxin on single-stranded (ss) and double-stranded (ds) DNAs (Figure 5). The 3'-phosphatase activity of LA on recessed, gapped or nicked ds DNA is approximately one-half of that on ss DNA (Figure 5A-C). In contrast, the 3'-PG hydrolase activity of LA on both ss and gapped ds DNA with 3'-PG ends is 1.5-fold higher than that on recessed or nicked ds DNA (Figure 5D-F). Figure 5.Aprataxin 3'-end processing activities on ss and ds DNA substrates. (A-C) 3'-Phosphatase activity of aprataxin on ss and ds DNA substrates. (A) The ss, recessed, one-nucleotide gapped and nicked DNA substrates with 3'-phosphate ends used are shown schematically. (B) Aprataxin preferentially acts on ss DNA. The substrates were incubated with 20 nM LA for the indicated times (0, 30, 60 and 90 min) at 37degreesC. Products were separated by denaturing PAGE and visualized using a Typhoon 9400 scanner (GE Healthcare). (C) Production rates in each reaction were quantified by ImageQuant TL (GE Healthcare). Error bars indicate standard errors for more than three independent experiments. (D-F) 3'-PG hydrolase activity of aprataxin on ss and ds DNA substrates. (D) The ss, recessed, one-nucleotide gapped and nicked DNA substrates with 3'-PG ends used are shown schematically. (E) Aprataxin preferentially acts on ss and gapped DNA. The substrates were incubated with 20 nM LA for the indicated times (0, 30, 60 and 90 min) at 37degreesC. (F) Production rates in each reaction were quantified as described above.
###end p 41
###begin p 42
###xml 69 72 69 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;C</bold>
###xml 688 691 682 685 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D&#8211;F</bold>
Aprataxin 3'-end processing activities on ss and ds DNA substrates. (A-C) 3'-Phosphatase activity of aprataxin on ss and ds DNA substrates. (A) The ss, recessed, one-nucleotide gapped and nicked DNA substrates with 3'-phosphate ends used are shown schematically. (B) Aprataxin preferentially acts on ss DNA. The substrates were incubated with 20 nM LA for the indicated times (0, 30, 60 and 90 min) at 37degreesC. Products were separated by denaturing PAGE and visualized using a Typhoon 9400 scanner (GE Healthcare). (C) Production rates in each reaction were quantified by ImageQuant TL (GE Healthcare). Error bars indicate standard errors for more than three independent experiments. (D-F) 3'-PG hydrolase activity of aprataxin on ss and ds DNA substrates. (D) The ss, recessed, one-nucleotide gapped and nicked DNA substrates with 3'-PG ends used are shown schematically. (E) Aprataxin preferentially acts on ss and gapped DNA. The substrates were incubated with 20 nM LA for the indicated times (0, 30, 60 and 90 min) at 37degreesC. (F) Production rates in each reaction were quantified as described above.
###end p 42
###begin title 43
Aprataxin removes adenylate residues covalently linked to 5'-phosphate ends, and disease-associated mutant forms of aprataxin lack the activity
###end title 43
###begin p 44
###xml 140 145 140 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12 B13 B14 B15">12&#8211;15</xref>
###xml 465 473 465 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 483 492 483 492 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6.</label>
###xml 583 584 583 584 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 601 602 601 602 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 492 1004 492 1004 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="45">Recombinant aprataxin fails to efficiently hydrolase GpppBODIPY or ApppBODIPY. GpppBODIPY (<bold>A</bold>) or ApppBODIPY (<bold>B</bold>) was incubated with recombinant His-tagged long-form aprataxin obtained from the baculovirus expression system (His-LA, lanes 4&#8211;6), recombinant GST fusion proteins containing LA (lanes 7 and 8), SA (lanes 9 and 10) and FHA (lanes 11 and 12). None of them showed lysine hydrolase activity (lanes 4&#8211;12). Fhit at 10 and 100&#8201;mU as the positive control showed GMP-lysine hydrolase activity (lanes 2 and 3).</p>
###xml 492 1004 492 1004 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="45">Recombinant aprataxin fails to efficiently hydrolase GpppBODIPY or ApppBODIPY. GpppBODIPY (<bold>A</bold>) or ApppBODIPY (<bold>B</bold>) was incubated with recombinant His-tagged long-form aprataxin obtained from the baculovirus expression system (His-LA, lanes 4&#8211;6), recombinant GST fusion proteins containing LA (lanes 7 and 8), SA (lanes 9 and 10) and FHA (lanes 11 and 12). None of them showed lysine hydrolase activity (lanes 4&#8211;12). Fhit at 10 and 100&#8201;mU as the positive control showed GMP-lysine hydrolase activity (lanes 2 and 3).</p></caption>
###xml 1004 1004 1004 1004 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm158f6"/>
###xml 483 1004 483 1004 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F6" position="float"><label>Figure 6.</label><caption><p textid="45">Recombinant aprataxin fails to efficiently hydrolase GpppBODIPY or ApppBODIPY. GpppBODIPY (<bold>A</bold>) or ApppBODIPY (<bold>B</bold>) was incubated with recombinant His-tagged long-form aprataxin obtained from the baculovirus expression system (His-LA, lanes 4&#8211;6), recombinant GST fusion proteins containing LA (lanes 7 and 8), SA (lanes 9 and 10) and FHA (lanes 11 and 12). None of them showed lysine hydrolase activity (lanes 4&#8211;12). Fhit at 10 and 100&#8201;mU as the positive control showed GMP-lysine hydrolase activity (lanes 2 and 3).</p></caption><graphic xlink:href="gkm158f6"/></fig>
As aprataxin has been reported to have GMP- and AMP-lysine hydrolase activities, which are present in most proteins of the HIT superfamily (12-15), we investigated the GMP- and AMP-lysine hydrolase activities of aprataxin employing GpppBODIPY and ApppBODIPY as substrates. The full-length aprataxin fusion proteins His-LA and LA showed very low or no GMP- or AMP-lysine hydrolase activity at the same or a higher concentration used for the 3'-end processing assay (Figure 6A and B). Figure 6.Recombinant aprataxin fails to efficiently hydrolase GpppBODIPY or ApppBODIPY. GpppBODIPY (A) or ApppBODIPY (B) was incubated with recombinant His-tagged long-form aprataxin obtained from the baculovirus expression system (His-LA, lanes 4-6), recombinant GST fusion proteins containing LA (lanes 7 and 8), SA (lanes 9 and 10) and FHA (lanes 11 and 12). None of them showed lysine hydrolase activity (lanes 4-12). Fhit at 10 and 100 mU as the positive control showed GMP-lysine hydrolase activity (lanes 2 and 3).
###end p 44
###begin p 45
###xml 91 92 91 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 109 110 109 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Recombinant aprataxin fails to efficiently hydrolase GpppBODIPY or ApppBODIPY. GpppBODIPY (A) or ApppBODIPY (B) was incubated with recombinant His-tagged long-form aprataxin obtained from the baculovirus expression system (His-LA, lanes 4-6), recombinant GST fusion proteins containing LA (lanes 7 and 8), SA (lanes 9 and 10) and FHA (lanes 11 and 12). None of them showed lysine hydrolase activity (lanes 4-12). Fhit at 10 and 100 mU as the positive control showed GMP-lysine hydrolase activity (lanes 2 and 3).
###end p 45
###begin p 46
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 422 430 422 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 599 607 599 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 617 626 617 626 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7.</label>
###xml 684 685 684 685 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 929 930 929 930 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1037 1038 1024 1025 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1492 1493 1479 1480 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 626 1626 626 1613 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="47">Removal of adenylate residues from 5&#8242;-ends by aprataxin. (<bold>A</bold>) Aprataxin removes AMP from 5&#8242;-ends of nicked ds DNA. The 45-mer ds DNA harboring a nick with 5&#8242;-AMP ends was incubated with the indicated amounts of aprataxin for 1&#8201;h. A band of the same size as that corresponding to the 5&#8242;-phosphate (5&#8242; &#8722; PO<sub>3</sub>&#8257; &#8722;) oligonucleotide appears in lanes with aprataxin. PNKP was used as the negative control. (<bold>B</bold>) Mutant forms of aprataxin fail to remove 5&#8242;-AMP. The 45-mer ds DNA harboring a nick with 5&#8242;-AMP ends was incubated in the presence of 50&#8201;nM recombinant GST fusion proteins containing LA (lanes 2&#8211;4), SA (lanes 5&#8211;7), FHA (lanes 8&#8211;10), P206L (lanes 11&#8211;13) and V263G (lanes 14&#8211;16) at different incubation times (0, 30 and 60&#8201;min). SA showed a lower 5&#8242;-AMP hydrolysis activity (lanes 5&#8211;7) than LA. Neither FHA, P206L nor V263G removed 5&#8242;-AMP (lanes 8&#8211;16). (<bold>C</bold>) Production rates in each reaction were quantified. Error bars indicate standard errors for more than three independent experiments.</p>
###xml 626 1626 626 1613 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="47">Removal of adenylate residues from 5&#8242;-ends by aprataxin. (<bold>A</bold>) Aprataxin removes AMP from 5&#8242;-ends of nicked ds DNA. The 45-mer ds DNA harboring a nick with 5&#8242;-AMP ends was incubated with the indicated amounts of aprataxin for 1&#8201;h. A band of the same size as that corresponding to the 5&#8242;-phosphate (5&#8242; &#8722; PO<sub>3</sub>&#8257; &#8722;) oligonucleotide appears in lanes with aprataxin. PNKP was used as the negative control. (<bold>B</bold>) Mutant forms of aprataxin fail to remove 5&#8242;-AMP. The 45-mer ds DNA harboring a nick with 5&#8242;-AMP ends was incubated in the presence of 50&#8201;nM recombinant GST fusion proteins containing LA (lanes 2&#8211;4), SA (lanes 5&#8211;7), FHA (lanes 8&#8211;10), P206L (lanes 11&#8211;13) and V263G (lanes 14&#8211;16) at different incubation times (0, 30 and 60&#8201;min). SA showed a lower 5&#8242;-AMP hydrolysis activity (lanes 5&#8211;7) than LA. Neither FHA, P206L nor V263G removed 5&#8242;-AMP (lanes 8&#8211;16). (<bold>C</bold>) Production rates in each reaction were quantified. Error bars indicate standard errors for more than three independent experiments.</p></caption>
###xml 1626 1626 1613 1613 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm158f7"/>
###xml 617 1626 617 1613 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F7" position="float"><label>Figure 7.</label><caption><p textid="47">Removal of adenylate residues from 5&#8242;-ends by aprataxin. (<bold>A</bold>) Aprataxin removes AMP from 5&#8242;-ends of nicked ds DNA. The 45-mer ds DNA harboring a nick with 5&#8242;-AMP ends was incubated with the indicated amounts of aprataxin for 1&#8201;h. A band of the same size as that corresponding to the 5&#8242;-phosphate (5&#8242; &#8722; PO<sub>3</sub>&#8257; &#8722;) oligonucleotide appears in lanes with aprataxin. PNKP was used as the negative control. (<bold>B</bold>) Mutant forms of aprataxin fail to remove 5&#8242;-AMP. The 45-mer ds DNA harboring a nick with 5&#8242;-AMP ends was incubated in the presence of 50&#8201;nM recombinant GST fusion proteins containing LA (lanes 2&#8211;4), SA (lanes 5&#8211;7), FHA (lanes 8&#8211;10), P206L (lanes 11&#8211;13) and V263G (lanes 14&#8211;16) at different incubation times (0, 30 and 60&#8201;min). SA showed a lower 5&#8242;-AMP hydrolysis activity (lanes 5&#8211;7) than LA. Neither FHA, P206L nor V263G removed 5&#8242;-AMP (lanes 8&#8211;16). (<bold>C</bold>) Production rates in each reaction were quantified. Error bars indicate standard errors for more than three independent experiments.</p></caption><graphic xlink:href="gkm158f7"/></fig>
Recently, Ahel et al. have shown that aprataxin removes the adenylate residues on 5'-ends of SSBs via its hydrolase activity, thus resolving the abortive DNA ligation intermediates (25). Therefore, we investigated the 5'-adenylate monophosphate (AMP) removal activity of our GST-aprataxin fusion proteins. As similarly observed in their previous study (25), LA removed an adenylate residue from a 5'-end of nicked ds DNA (Figure 7A). In addition, SA showed a much lower 5'-AMP removal activity than LA, and FHA and disease-associated mutant forms (P206L and V263G) of aprataxin lacked the activity (Figure 7)B and C. Figure 7.Removal of adenylate residues from 5'-ends by aprataxin. (A) Aprataxin removes AMP from 5'-ends of nicked ds DNA. The 45-mer ds DNA harboring a nick with 5'-AMP ends was incubated with the indicated amounts of aprataxin for 1 h. A band of the same size as that corresponding to the 5'-phosphate (5' - PO3insertion mark -) oligonucleotide appears in lanes with aprataxin. PNKP was used as the negative control. (B) Mutant forms of aprataxin fail to remove 5'-AMP. The 45-mer ds DNA harboring a nick with 5'-AMP ends was incubated in the presence of 50 nM recombinant GST fusion proteins containing LA (lanes 2-4), SA (lanes 5-7), FHA (lanes 8-10), P206L (lanes 11-13) and V263G (lanes 14-16) at different incubation times (0, 30 and 60 min). SA showed a lower 5'-AMP hydrolysis activity (lanes 5-7) than LA. Neither FHA, P206L nor V263G removed 5'-AMP (lanes 8-16). (C) Production rates in each reaction were quantified. Error bars indicate standard errors for more than three independent experiments.
###end p 46
###begin p 47
###xml 58 59 58 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 303 304 303 304 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 411 412 398 399 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 866 867 853 854 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
Removal of adenylate residues from 5'-ends by aprataxin. (A) Aprataxin removes AMP from 5'-ends of nicked ds DNA. The 45-mer ds DNA harboring a nick with 5'-AMP ends was incubated with the indicated amounts of aprataxin for 1 h. A band of the same size as that corresponding to the 5'-phosphate (5' - PO3insertion mark -) oligonucleotide appears in lanes with aprataxin. PNKP was used as the negative control. (B) Mutant forms of aprataxin fail to remove 5'-AMP. The 45-mer ds DNA harboring a nick with 5'-AMP ends was incubated in the presence of 50 nM recombinant GST fusion proteins containing LA (lanes 2-4), SA (lanes 5-7), FHA (lanes 8-10), P206L (lanes 11-13) and V263G (lanes 14-16) at different incubation times (0, 30 and 60 min). SA showed a lower 5'-AMP hydrolysis activity (lanes 5-7) than LA. Neither FHA, P206L nor V263G removed 5'-AMP (lanes 8-16). (C) Production rates in each reaction were quantified. Error bars indicate standard errors for more than three independent experiments.
###end p 47
###begin title 48
###xml 38 43 <span type="species:ncbi:9606">human</span>
Reconstitution of SSBR by recombinant human aprataxin, Pol beta and Lig3
###end title 48
###begin p 49
###xml 390 398 384 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 731 739 722 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 1063 1071 1051 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 1269 1278 1254 1263 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8.</label>
###xml 1324 1325 1309 1310 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1479 1480 1464 1465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 2053 2054 2025 2026 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1278 2781 1263 2753 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="50">Aprataxin repairs SSBs with damaged 3&#8242;-ends. (<bold>A</bold>) DNA repair assay employing gapped dsDNA with 3&#8242;-phosphate ends as substrate. The 45-mer ds DNA substrate harboring a 1-nt gap with 3&#8242;-phosphate (3&#8242; &#8722; PO<sub>3</sub>&#8257; &#8722;) ends was incubated in the absence (lane 3) or presence of each of the indicated recombinant human proteins for 90&#8201;min (lanes 4&#8211;9). The 45-mer ds DNA substrate, harboring a 1-nt gap with 3&#8242;-hydroxyl (3&#8242;-OH) ends, was incubated in the absence (lane 1) or presence of each indicated recombinant human protein (lane 2). Complete repair is indicated by the generation of the 5&#8242;-FITC-labeled 45-mer oligonucleotide. The amount of 5&#8242;-FITC-labeled 45-mer increased with the concentration of aprataxin (lanes 6&#8211;8). PNKP was used as the positive control (lane 9). (<bold>B</bold>) DNA repair assay employing gapped dsDNA with 3&#8242;-phosphoglycolate ends as substrate. The 45-mer duplex substrate harboring a 1-nt gap with 3&#8242;-phosphoglycolate (3&#8242;-PG) ends was incubated in the absence (lane 3) or presence of each of the indicated recombinant human proteins for 90&#8201;min (lanes 4&#8211;9). The 45-mer duplex substrate harboring a 1-nt gap with 3&#8242;-OH ends was incubated in the absence (lane 1) or presence of each indicated recombinant human protein (lane 2). The amount of the FITC-labeled 45-mer oligonucleotide increases with aprataxin concentration (lanes 6&#8211;8). APE1 was used as the positive control (lane 9). The structures of the substrates employed in these experiments are shown on the right side of each panel.</p>
###xml 1278 2781 1263 2753 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="50">Aprataxin repairs SSBs with damaged 3&#8242;-ends. (<bold>A</bold>) DNA repair assay employing gapped dsDNA with 3&#8242;-phosphate ends as substrate. The 45-mer ds DNA substrate harboring a 1-nt gap with 3&#8242;-phosphate (3&#8242; &#8722; PO<sub>3</sub>&#8257; &#8722;) ends was incubated in the absence (lane 3) or presence of each of the indicated recombinant human proteins for 90&#8201;min (lanes 4&#8211;9). The 45-mer ds DNA substrate, harboring a 1-nt gap with 3&#8242;-hydroxyl (3&#8242;-OH) ends, was incubated in the absence (lane 1) or presence of each indicated recombinant human protein (lane 2). Complete repair is indicated by the generation of the 5&#8242;-FITC-labeled 45-mer oligonucleotide. The amount of 5&#8242;-FITC-labeled 45-mer increased with the concentration of aprataxin (lanes 6&#8211;8). PNKP was used as the positive control (lane 9). (<bold>B</bold>) DNA repair assay employing gapped dsDNA with 3&#8242;-phosphoglycolate ends as substrate. The 45-mer duplex substrate harboring a 1-nt gap with 3&#8242;-phosphoglycolate (3&#8242;-PG) ends was incubated in the absence (lane 3) or presence of each of the indicated recombinant human proteins for 90&#8201;min (lanes 4&#8211;9). The 45-mer duplex substrate harboring a 1-nt gap with 3&#8242;-OH ends was incubated in the absence (lane 1) or presence of each indicated recombinant human protein (lane 2). The amount of the FITC-labeled 45-mer oligonucleotide increases with aprataxin concentration (lanes 6&#8211;8). APE1 was used as the positive control (lane 9). The structures of the substrates employed in these experiments are shown on the right side of each panel.</p></caption>
###xml 2781 2781 2753 2753 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm158f8"/>
###xml 1269 2781 1254 2753 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F8" position="float"><label>Figure 8.</label><caption><p textid="50">Aprataxin repairs SSBs with damaged 3&#8242;-ends. (<bold>A</bold>) DNA repair assay employing gapped dsDNA with 3&#8242;-phosphate ends as substrate. The 45-mer ds DNA substrate harboring a 1-nt gap with 3&#8242;-phosphate (3&#8242; &#8722; PO<sub>3</sub>&#8257; &#8722;) ends was incubated in the absence (lane 3) or presence of each of the indicated recombinant human proteins for 90&#8201;min (lanes 4&#8211;9). The 45-mer ds DNA substrate, harboring a 1-nt gap with 3&#8242;-hydroxyl (3&#8242;-OH) ends, was incubated in the absence (lane 1) or presence of each indicated recombinant human protein (lane 2). Complete repair is indicated by the generation of the 5&#8242;-FITC-labeled 45-mer oligonucleotide. The amount of 5&#8242;-FITC-labeled 45-mer increased with the concentration of aprataxin (lanes 6&#8211;8). PNKP was used as the positive control (lane 9). (<bold>B</bold>) DNA repair assay employing gapped dsDNA with 3&#8242;-phosphoglycolate ends as substrate. The 45-mer duplex substrate harboring a 1-nt gap with 3&#8242;-phosphoglycolate (3&#8242;-PG) ends was incubated in the absence (lane 3) or presence of each of the indicated recombinant human proteins for 90&#8201;min (lanes 4&#8211;9). The 45-mer duplex substrate harboring a 1-nt gap with 3&#8242;-OH ends was incubated in the absence (lane 1) or presence of each indicated recombinant human protein (lane 2). The amount of the FITC-labeled 45-mer oligonucleotide increases with aprataxin concentration (lanes 6&#8211;8). APE1 was used as the positive control (lane 9). The structures of the substrates employed in these experiments are shown on the right side of each panel.</p></caption><graphic xlink:href="gkm158f8"/></fig>
###xml 1590 1595 <span type="species:ncbi:9606">human</span>
###xml 1790 1795 <span type="species:ncbi:9606">human</span>
###xml 2314 2319 <span type="species:ncbi:9606">human</span>
###xml 2498 2503 <span type="species:ncbi:9606">human</span>
To confirm that the 3'-end processing activity of aprataxin is sufficient for SSBR by following the reactions carried out by Pol beta and Lig3, we then reconstituted SSBR using gapped ds DNA with damaged 3'-ends as substrates. In this assay, aprataxin was assumed to restore damaged 3'-ends including 3'-phosphate and 3'-PG ends to 3'-hydroxyl ends that are suitable for Pol beta and Lig3 (Figure 8A and B, right panel). First, we incubated the gapped ds DNA consisting of 3'-phosphate 21-mer oligonucleotides and 5'-phosphate 23-mer oligonucleotides annealed to complementary 45-mer oligonucleotides with Pol beta and Lig3 in the presence or absence of His-LA. Here, 45-mer products were generated only in the presence of His-LA (Figure 8A, left panel). Next, we incubated gapped ds DNA consisting of 3'-PG 21-mer oligonucleotides and 5'-phosphate 23-mer oligonucleotides annealed to complementary 45-mer oligonucleotides with Pol beta and Lig3 in the presence or absence of His-LA. As expected, 45-mer products were generated only in the presence of aprataxin (Figure 8B, left panel). These results clearly indicate that the 3'-phosphate and 3'-PG removal activities of aprataxin are sufficient for the 3'-end processing in reconstituted SSBR with Pol beta and Lig3. Figure 8.Aprataxin repairs SSBs with damaged 3'-ends. (A) DNA repair assay employing gapped dsDNA with 3'-phosphate ends as substrate. The 45-mer ds DNA substrate harboring a 1-nt gap with 3'-phosphate (3' - PO3insertion mark -) ends was incubated in the absence (lane 3) or presence of each of the indicated recombinant human proteins for 90 min (lanes 4-9). The 45-mer ds DNA substrate, harboring a 1-nt gap with 3'-hydroxyl (3'-OH) ends, was incubated in the absence (lane 1) or presence of each indicated recombinant human protein (lane 2). Complete repair is indicated by the generation of the 5'-FITC-labeled 45-mer oligonucleotide. The amount of 5'-FITC-labeled 45-mer increased with the concentration of aprataxin (lanes 6-8). PNKP was used as the positive control (lane 9). (B) DNA repair assay employing gapped dsDNA with 3'-phosphoglycolate ends as substrate. The 45-mer duplex substrate harboring a 1-nt gap with 3'-phosphoglycolate (3'-PG) ends was incubated in the absence (lane 3) or presence of each of the indicated recombinant human proteins for 90 min (lanes 4-9). The 45-mer duplex substrate harboring a 1-nt gap with 3'-OH ends was incubated in the absence (lane 1) or presence of each indicated recombinant human protein (lane 2). The amount of the FITC-labeled 45-mer oligonucleotide increases with aprataxin concentration (lanes 6-8). APE1 was used as the positive control (lane 9). The structures of the substrates employed in these experiments are shown on the right side of each panel.
###end p 49
###begin p 50
###xml 46 47 46 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 201 202 201 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 775 776 762 763 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 312 317 <span type="species:ncbi:9606">human</span>
###xml 512 517 <span type="species:ncbi:9606">human</span>
###xml 1036 1041 <span type="species:ncbi:9606">human</span>
###xml 1220 1225 <span type="species:ncbi:9606">human</span>
Aprataxin repairs SSBs with damaged 3'-ends. (A) DNA repair assay employing gapped dsDNA with 3'-phosphate ends as substrate. The 45-mer ds DNA substrate harboring a 1-nt gap with 3'-phosphate (3' - PO3insertion mark -) ends was incubated in the absence (lane 3) or presence of each of the indicated recombinant human proteins for 90 min (lanes 4-9). The 45-mer ds DNA substrate, harboring a 1-nt gap with 3'-hydroxyl (3'-OH) ends, was incubated in the absence (lane 1) or presence of each indicated recombinant human protein (lane 2). Complete repair is indicated by the generation of the 5'-FITC-labeled 45-mer oligonucleotide. The amount of 5'-FITC-labeled 45-mer increased with the concentration of aprataxin (lanes 6-8). PNKP was used as the positive control (lane 9). (B) DNA repair assay employing gapped dsDNA with 3'-phosphoglycolate ends as substrate. The 45-mer duplex substrate harboring a 1-nt gap with 3'-phosphoglycolate (3'-PG) ends was incubated in the absence (lane 3) or presence of each of the indicated recombinant human proteins for 90 min (lanes 4-9). The 45-mer duplex substrate harboring a 1-nt gap with 3'-OH ends was incubated in the absence (lane 1) or presence of each indicated recombinant human protein (lane 2). The amount of the FITC-labeled 45-mer oligonucleotide increases with aprataxin concentration (lanes 6-8). APE1 was used as the positive control (lane 9). The structures of the substrates employed in these experiments are shown on the right side of each panel.
###end p 50
###begin title 51
DISCUSSION
###end title 51
###begin p 52
Here, we show that aprataxin specifically removes damaged 3'-ends including 3'-PG and 3'-phosphate ends. Through this action, aprataxin might act with DNA polymerase and ligase to repair SSBs with these damaged 3'-ends. In addition, the C-terminal region of aprataxin is responsible for the removal activity and the region of 1-174 amino acids of aprataxin might enhance the removal activity. Furthermore, the disease-associated mutant forms of aprataxin P206L and V263G lack the removal activity, strongly suggesting that the loss of the removal activity of aprataxin is closely linked to the pathogenesis of EAOH/AOA1.
###end p 52
###begin p 53
###xml 313 315 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 316 318 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 537 539 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 542 550 535 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F9">Figure 9</xref>
###xml 759 761 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 762 764 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 987 992 973 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21 B22 B23">21&#8211;23</xref>
###xml 1827 1835 1799 1807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F9">Figure 9</xref>
###xml 1934 1942 1906 1914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F9">Figure 9</xref>
###xml 2021 2023 1993 1995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 2132 2140 2104 2112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F9">Figure 9</xref>
###xml 2252 2261 2224 2233 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 9.</label>
###xml 2706 2707 2678 2679 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</bold>
###xml 2771 2772 2743 2744 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</bold>
###xml 2786 2787 2758 2759 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</bold>
###xml 2796 2797 2768 2769 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</bold>
###xml 2808 2809 2780 2781 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</bold>
###xml 3353 3354 3318 3319 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</bold>
###xml 3428 3429 3390 3391 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</bold>
###xml 2261 3476 2233 3438 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="54">Model of aprataxin-dependent SSBR pathway. Four SSBR pathways defined by the type of enzyme that removes damaged 3&#8242;-ends are shown (a, b, c and d). SSBs can arise directly from sugar damage or TOP1 cleavage or indirectly from base damage. Red circles denote the damaged ends, the specific types of which are dependent on the source of the break. [1,2] PARP detects SSBs, thereby recruiting the XRCC1 and Lig3 complex. XRCC1 then replaces PARP. [<bold>3</bold>] The processing of damaged 3&#8242;-ends is mediated by either APE1 (<bold>a</bold>), aprataxin (<bold>b</bold>), PNKP (<bold>c</bold>) or TDP1 (<bold>d</bold>), depending on the type of damaged 3&#8242;-end. These damaged 3&#8242;-ends should be converted to 3&#8242;-OH ends for subsequent repair processes. In the pathway for repairing indirectly induced SSBs, damaged 3&#8242;-&#945;, &#946; unsaturated aldehyde ends are removed by APE1 (a). In the pathway for repairing directly induced SSBs, 3&#8242;-PG ends might be removed by aprataxin (b) and 3&#8242;-phosphate ends by aprataxin or PNKP (b,c). In the pathway for repairing TOP1-mediated SSBs, TOP1 covalent complexes at the 3&#8242;-ends are restored to 3&#8242;-phosphate ends by TDP1 (d). [<bold>4</bold>] After removing damaged 3&#8242;-ends, Pol &#946; fills the gap (red dot line). [<bold>5</bold>] Lig3 seals the single-strand nick (red line).</p>
###xml 2261 3476 2233 3438 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="54">Model of aprataxin-dependent SSBR pathway. Four SSBR pathways defined by the type of enzyme that removes damaged 3&#8242;-ends are shown (a, b, c and d). SSBs can arise directly from sugar damage or TOP1 cleavage or indirectly from base damage. Red circles denote the damaged ends, the specific types of which are dependent on the source of the break. [1,2] PARP detects SSBs, thereby recruiting the XRCC1 and Lig3 complex. XRCC1 then replaces PARP. [<bold>3</bold>] The processing of damaged 3&#8242;-ends is mediated by either APE1 (<bold>a</bold>), aprataxin (<bold>b</bold>), PNKP (<bold>c</bold>) or TDP1 (<bold>d</bold>), depending on the type of damaged 3&#8242;-end. These damaged 3&#8242;-ends should be converted to 3&#8242;-OH ends for subsequent repair processes. In the pathway for repairing indirectly induced SSBs, damaged 3&#8242;-&#945;, &#946; unsaturated aldehyde ends are removed by APE1 (a). In the pathway for repairing directly induced SSBs, 3&#8242;-PG ends might be removed by aprataxin (b) and 3&#8242;-phosphate ends by aprataxin or PNKP (b,c). In the pathway for repairing TOP1-mediated SSBs, TOP1 covalent complexes at the 3&#8242;-ends are restored to 3&#8242;-phosphate ends by TDP1 (d). [<bold>4</bold>] After removing damaged 3&#8242;-ends, Pol &#946; fills the gap (red dot line). [<bold>5</bold>] Lig3 seals the single-strand nick (red line).</p></caption>
###xml 3476 3476 3438 3438 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm158f9"/>
###xml 2252 3476 2224 3438 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F9" position="float"><label>Figure 9.</label><caption><p textid="54">Model of aprataxin-dependent SSBR pathway. Four SSBR pathways defined by the type of enzyme that removes damaged 3&#8242;-ends are shown (a, b, c and d). SSBs can arise directly from sugar damage or TOP1 cleavage or indirectly from base damage. Red circles denote the damaged ends, the specific types of which are dependent on the source of the break. [1,2] PARP detects SSBs, thereby recruiting the XRCC1 and Lig3 complex. XRCC1 then replaces PARP. [<bold>3</bold>] The processing of damaged 3&#8242;-ends is mediated by either APE1 (<bold>a</bold>), aprataxin (<bold>b</bold>), PNKP (<bold>c</bold>) or TDP1 (<bold>d</bold>), depending on the type of damaged 3&#8242;-end. These damaged 3&#8242;-ends should be converted to 3&#8242;-OH ends for subsequent repair processes. In the pathway for repairing indirectly induced SSBs, damaged 3&#8242;-&#945;, &#946; unsaturated aldehyde ends are removed by APE1 (a). In the pathway for repairing directly induced SSBs, 3&#8242;-PG ends might be removed by aprataxin (b) and 3&#8242;-phosphate ends by aprataxin or PNKP (b,c). In the pathway for repairing TOP1-mediated SSBs, TOP1 covalent complexes at the 3&#8242;-ends are restored to 3&#8242;-phosphate ends by TDP1 (d). [<bold>4</bold>] After removing damaged 3&#8242;-ends, Pol &#946; fills the gap (red dot line). [<bold>5</bold>] Lig3 seals the single-strand nick (red line).</p></caption><graphic xlink:href="gkm158f9"/></fig>
The removal of damaged 3'-ends is important for repairing SSBs. SSBs arising directly from sugar damage usually possess 3'-phosphate or 3'-PG ends, whereas SSBs arising indirectly from base damage, via the enzymatic cleavage of the DNA backbone, possess 3'-alpha, beta-unsaturated aldehyde, or 3'-phosphate ends (16,26). The formation of another type of SSB is mediated by TOP1, which cleaves one strand of a ds DNA during transcription or DNA replication and covalently binds at the 3'-ends with the tyrosyl-DNA phosphodiester linkage (17) (Figure 9). Several enzymes including a multiprotein complex with XRCC1 have been proposed as candidates for removing these damaged 3'-ends. PNKP might restore damaged 3'-phosphate ends, but not other damaged 3'-ends (23,27). APE1 is assumed to remove damaged 3'-phosphate, 3'-PG or 3'-alpha, beta-unsaturated aldehyde ends; however, its enzymatic activity for removing 3'-phosphate or 3'-PG is extremely lower than its AP endonuclease activity (21-23). The results using fusion proteins expressed in baculovirus and bacterial expression systems clearly showed that aprataxin restores the damaged 3'-PG and 3'-phosphate ends to 3'-hydroxyl ends, but not 3'-alpha, beta-unsaturated aldehyde ends nor phosphotyrosine ends. Moreover, the 3'-PG removal activity of aprataxin is higher than that of APE1 and prefers the gapped ds DNA as well as ss DNA, although the 3'-phosphate removal activity of aprataxin is lower than that of PNKP and prefers the ss DNA, not ds DNA. The results suggest that aprataxin is associated with the removal of damaged 3'-ends, particularly 3'-PG ends, directly induced by sugar damage, whereas APE1 is associated with the removal of damaged 3'-alpha, beta-unsaturated aldehyde ends induced by base damage as well as the endonucleolytic cleavage of an AP site (Figure 9A and B). By contrast, although both PNKP and aprataxin might restore damaged 3'-phospohate ends, (Figure 9B and C), these proteins are found in mutually exclusive complexes with XRCC1 (28); therefore, they might function independently of each other in the repair of SSBs induced by sugar damage (Figure 9B and C). The precise physiological roles of PNKP and aprataxin in SSBR, however, await further investigations. Figure 9.Model of aprataxin-dependent SSBR pathway. Four SSBR pathways defined by the type of enzyme that removes damaged 3'-ends are shown (a, b, c and d). SSBs can arise directly from sugar damage or TOP1 cleavage or indirectly from base damage. Red circles denote the damaged ends, the specific types of which are dependent on the source of the break. [1,2] PARP detects SSBs, thereby recruiting the XRCC1 and Lig3 complex. XRCC1 then replaces PARP. [3] The processing of damaged 3'-ends is mediated by either APE1 (a), aprataxin (b), PNKP (c) or TDP1 (d), depending on the type of damaged 3'-end. These damaged 3'-ends should be converted to 3'-OH ends for subsequent repair processes. In the pathway for repairing indirectly induced SSBs, damaged 3'-alpha, beta unsaturated aldehyde ends are removed by APE1 (a). In the pathway for repairing directly induced SSBs, 3'-PG ends might be removed by aprataxin (b) and 3'-phosphate ends by aprataxin or PNKP (b,c). In the pathway for repairing TOP1-mediated SSBs, TOP1 covalent complexes at the 3'-ends are restored to 3'-phosphate ends by TDP1 (d). [4] After removing damaged 3'-ends, Pol beta fills the gap (red dot line). [5] Lig3 seals the single-strand nick (red line).
###end p 53
###begin p 54
###xml 445 446 445 446 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</bold>
###xml 510 511 510 511 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</bold>
###xml 525 526 525 526 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</bold>
###xml 535 536 535 536 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</bold>
###xml 547 548 547 548 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</bold>
###xml 1092 1093 1085 1086 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</bold>
###xml 1167 1168 1157 1158 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</bold>
Model of aprataxin-dependent SSBR pathway. Four SSBR pathways defined by the type of enzyme that removes damaged 3'-ends are shown (a, b, c and d). SSBs can arise directly from sugar damage or TOP1 cleavage or indirectly from base damage. Red circles denote the damaged ends, the specific types of which are dependent on the source of the break. [1,2] PARP detects SSBs, thereby recruiting the XRCC1 and Lig3 complex. XRCC1 then replaces PARP. [3] The processing of damaged 3'-ends is mediated by either APE1 (a), aprataxin (b), PNKP (c) or TDP1 (d), depending on the type of damaged 3'-end. These damaged 3'-ends should be converted to 3'-OH ends for subsequent repair processes. In the pathway for repairing indirectly induced SSBs, damaged 3'-alpha, beta unsaturated aldehyde ends are removed by APE1 (a). In the pathway for repairing directly induced SSBs, 3'-PG ends might be removed by aprataxin (b) and 3'-phosphate ends by aprataxin or PNKP (b,c). In the pathway for repairing TOP1-mediated SSBs, TOP1 covalent complexes at the 3'-ends are restored to 3'-phosphate ends by TDP1 (d). [4] After removing damaged 3'-ends, Pol beta fills the gap (red dot line). [5] Lig3 seals the single-strand nick (red line).
###end p 54
###begin p 55
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1013 1021 <span type="species:ncbi:9606">patients</span>
In DNA ligation, DNA ligase transfers AMP residues to 5'-ends of the DNA breaks and catalyzes the displacement of the adenylate residues on 5'-ends by attacking the adjacent 3'-hydroxyl group. When 3'-ends are damaged and non-ligated, the adenylate residues remain on 5'-ends of SSBs as abortive DNA-ligation intermediates. Recently, Ahel et al. have shown that aprataxin removes the adenylate residues on 5'-ends of SSBs (25). As reported in their article (25), aprataxin used in the present study also removed an adenylate residue from a 5'-end of nicked ds DNA. These results indicate that aprataxin contributes to processing the 'dirty ends', both 3'- and 5'-ends, of the DNA breaks. Furthermore, the disease-associated mutant forms of aprataxin lost their 3'- and 5'-end processing activities, suggesting the importance of the activities for EAOH/AOA1 pathogenesis. To determine the main physiological role of aprataxin in SSBR, we have to show the accumulation of SSBs with these dirty ends in tissues from patients with EAOH/AOA1 in future studies.
###end p 55
###begin p 56
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
The clinical phenotype of EAOH/AOA1 is specifically restricted to the nervous system, raising the possibility that the activity of aprataxin to remove 3'-phosphate or 3'-PG ends plays an important role in neurons. Tyrosyl-DNA phosphodiesterase 1 (TDP1), the causative gene product for spinocerebellar ataxia with axonal neuropathy type 1 (SCAN1), removes the TOP1 peptide from 3'-ends in SSBs induced by TOP1. In addition to its tyrosyl-DNA phosphodiesterase activity, TDP1 has been also proposed to remove 3'-PG ends and function in the repair of SSBs induced by oxidative stress (17,29). The clinical phenotype of SCAN1 is similar to that of EAOH/AOA1, because they include cerebellar degeneration, posterior column involvement and peripheral axonal neuropathy without predisposition to malignancy (30). These similarities between EAOH/AOA1 and SCAN1 suggest that the removal of damaged 3'-ends, particularly those induced by oxidative stress, is crucial for the viability and function of neurons, in particular Purkinje cells and dorsal root ganglion cells.
###end p 56
###begin p 57
The unique properties of neurons including a high rate of ROS production and a high transcriptional activity may lead to the generation of more SSBs compared with non-neuronal cells. Furthermore, although mitotic cells can utilize a homologous recombination machinery to compensate for a defect in SSBR, postmitotic neurons are unable to repair damaged DNA molecules in a DNA-replication-dependent manner and they are highly dependent on SSBR for DNA integrity. Therefore, neurons might be vulnerable to a defect in SSBR. The reason why a specific neuronal subtype is vulnerable to impairment of the aprataxin-dependent or TDP1-dependent SSBR system remains to be elucidated. Further studies on the mechanism underlying neuronal death and dysfunction caused by a defect in SSBR should provide new insights into therapeutic approaches for neurodegenerative disorders.
###end p 57
###begin title 58
SUPPLEMENTARY DATA
###end title 58
###begin p 59
Supplementary Data is available at NAR online.
###end p 59
###begin title 60
Supplementary Material
###end title 60
###begin title 61
[Supplementary Material]
###end title 61
###begin title 62
ACKNOWLEDGEMENTS
###end title 62
###begin p 63
This study was supported in part by a Grant-in-Aid for Scientific Research on Priority Areas 'Advanced Brain Science Project' and 'Applied Genomics', a Grant-in-Aid for Scientific Research (A) and (B) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a grant for the Research for the Future Program from the Japan Society for the Promotion of Science, a grant for 'the Research Committee for Ataxic Diseases' of the Research on Measures for Intractable Diseases from the Ministry of Health, Labor and Welfare, Japan, a grant from the Virtual Research Institute of Aging of Nippon Boehringer Ingelheim, a grant from the Naito Foundation, and grants from the Takeda Science Foundation, Suzuken Memorial Foundation, and Tsubaki Memorial Neuroscience Research Foundation. 'the Research Committee for Ataxic Diseases' of the Research on Measures for Intractable Diseases from the Ministry of Health, Welfare and Labour, Japan. Funding to pay the Open Access publication charge was provided by A Grant-in-Aid for Scientific Research on Priority Areas "Applied Genomics".
###end p 63
###begin p 64
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 64
###begin title 65
REFERENCES
###end title 65
###begin article-title 66
Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene
###end article-title 66
###begin article-title 67
The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin
###end article-title 67
###begin article-title 68
Hereditary motor and sensory neuropathy associated with cerebellar atrophy (HMSNCA): a new disease
###end article-title 68
###begin article-title 69
Ataxia-ocular motor apraxia: a syndrome mimicking ataxia-telangiectasia
###end article-title 69
###begin article-title 70
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Recessive ataxia with ocular apraxia: review of 22 Portuguese patients
###end article-title 70
###begin article-title 71
Hereditary motor and sensory neuropathy associated with cerebellar atrophy (HMSNCA): clinical and neuropathological features of a Japanese family
###end article-title 71
###begin article-title 72
The FHA domain of aprataxin interacts with the C-terminal region of XRCC1
###end article-title 72
###begin article-title 73
XRCC1 and DNA strand break repair
###end article-title 73
###begin article-title 74
The ataxia-oculomotor apraxia 1 gene product has a role distinct from ATM and interacts with the DNA strand break repair proteins XRCC1 and XRCC4
###end article-title 74
###begin article-title 75
Aprataxin, the causative protein for EAOH is a nuclear protein with a potential role as a DNA repair protein
###end article-title 75
###begin article-title 76
Aprataxin, a novel protein that protects against genotoxic stress
###end article-title 76
###begin article-title 77
Loss of function mechanism in aprataxin-related early-onset ataxia
###end article-title 77
###begin article-title 78
Disease-associated mutations inactivate AMP-lysine hydrolase activity of Aprataxin
###end article-title 78
###begin article-title 79
Aprataxin forms a discrete branch in the HIT (histidine triad) superfamily of proteins with both DNA/RNA binding and nucleotide hydrolase activities
###end article-title 79
###begin article-title 80
Fhit-nucleotide specificity probed with novel fluorescent and fluorogenic substrates
###end article-title 80
###begin article-title 81
Mammalian DNA single-strand break repair: an X-ra(y)ted affair
###end article-title 81
###begin article-title 82
Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1
###end article-title 82
###begin article-title 83
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human DNA topoisomerase I: relaxation, roles, and damage control
###end article-title 83
###begin article-title 84
DNA single-strand breaks and neurodegeneration
###end article-title 84
###begin article-title 85
###xml 50 55 <span type="species:ncbi:9606">human</span>
APE1 is the major 3'-phosphoglycolate activity in human cell extracts
###end article-title 85
###begin article-title 86
###xml 107 112 <span type="species:ncbi:9606">human</span>
Removal of 3'-phosphoglycolate from DNA strand-break damage in an oligonucleotide substrate by recombinant human apurinic/apyrimidinic endonuclease 1
###end article-title 86
###begin article-title 87
###xml 33 38 <span type="species:ncbi:9606">human</span>
3'-Phosphodiesterase activity of human apurinic/apyrimidinic endonuclease at DNA double-strand break ends
###end article-title 87
###begin article-title 88
###xml 56 61 <span type="species:ncbi:9606">human</span>
AP endonuclease-independent DNA base excision repair in human cells
###end article-title 88
###begin article-title 89
Making AppDNA using T4 DNA ligase
###end article-title 89
###begin article-title 90
The neurodegenerative disease protein aprataxin resolves abortive DNA ligation intermediates
###end article-title 90
###begin article-title 91
###xml 59 84 59 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Schizosaccharomyces pombe</italic>
###xml 59 84 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
Roles of base excision repair enzymes Nth1p and Apn2p from Schizosaccharomyces pombe in processing alkylation and oxidative DNA damage
###end article-title 91
###begin article-title 92
###xml 103 108 <span type="species:ncbi:9606">human</span>
Conversion of phosphoglycolate to phosphate termini on 3' overhangs of DNA double strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1
###end article-title 92
###begin article-title 93
A new XRCC1-containing complex and its role in cellular survival of methyl methanesulfonate treatment
###end article-title 93
###begin article-title 94
###xml 48 53 <span type="species:ncbi:9606">human</span>
Deficiency in 3'-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1)
###end article-title 94
###begin article-title 95
Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy
###end article-title 95
###begin p 96
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors
###end p 96

